Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Virginia's Medicaid Pharmacy Benefits Management System
Phone: 800-932-6648 Fax: 800-932-6651

General Information:

- **Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary only includes select drug classes, other classes will pay such as but not limited to diuretics, many cardiac agents, many antibiotics etc.**
- PDL preferred drugs do not require Service Authorizations (SA) unless subject to additional clinical criteria (e.g., long-acting opioids, hepatitis C therapies, growth hormone)
- Non-preferred drugs require a SA
- Drugs not on the PDL are subject to Virginia's mandatory generic substitution requirements.
- SAs may be submitted by fax, phone or WebPA, e-PA. For urgent requests, please call **800-932-6648.** Fax requests receive a response within 24 hours.

PDL drug coverage information can be found at http://www.VirginiaMedicaidPharmacyServices.com. **The following "routine" PDL criteria guidelines will be applied to all non-preferred drugs.**

1. Is there any reason the member cannot be changed to a preferred drug within the same class? Acceptable reasons include:
   - Allergy to preferred drug.
   - Contraindication to or drug-to-drug interaction with preferred drug.
   - History of unacceptable/toxic side effects to preferred drug.
   - Member's condition is clinically stable; changing to a preferred drug might cause deterioration of the member's condition.
2. The requested drug may be approved if both of the following are true:
   - There has been a therapeutic failure of at least **two** preferred drugs **within the same class as appropriate for diagnosis unless otherwise noted in the clinical criteria**. A therapeutic failure of only one preferred drug is required when there is only one preferred drug within a therapeutic class.
   - The requested drug's corresponding generic (if a generic is available **and** covered by the State) has been attempted and failed or is contraindicated.

All changes from the last post will be highlighted in yellow.
Drugs highlighted in blue indicate where brand is preferred over generic.

LEGEND

AGE = age edit
CE= clinical edit
ST = step edit
QL = quantity limit
cap = capsule
cr = cream
ER = extended release
inj = injection
IR = immediate release
ODT = oral disintegrating tab
oint = ointment
soln = solution
supp = suppository
susp = suspension
tab = tab
♦ = Clinical Utilization Edit

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Analgesics		
***♦ Opioids – Long Acting (LAO)**		
Preferred (Sch III-VI)	***Non-Preferred***	***All Long-Acting Opioids (preferred and non-preferred) require submission of a Clinical SA. Refer to combined short/long-acting opioid SA form (Short & Long Acting Opioid SA Form)** **LENGTH OF AUTHORIZATIONS** • Up to 3 months for (includes HIV/AIDS, Chronic back pain, Arthritis, Fibromyalgia, Diabetic neuropathy, Postherpetic Neuralgia). • Up to 6 months for chronic pain (includes Cancer pain, Sickle cell disease, Palliative care, End-of-Life Care, Hospice). Daily dose limits have been established for all LAO. Quantity limits can be found at: **Daily Dose Limits for Short & Long Acting Opioids**
Butrans® (buprenorphine) Transdermal Patch	*Belbuca (buprenorphine buccal film)* *buprenorphine (gen Butrans®)* *buprenorphine (gen Belbuca)* *ConZip® (tramadol ER)* *Ryzolt™ (tramadol ER)* *tramadol ER* *Ultram ER® (tramadol ER)*	
Preferred (Sch II)	***Non-Preferred***	
fentanyl 12, 25, 50, 75 & 100 mcg patches **morphine sulfate ER tab**	*Arymo™ER* *Embeda* *Exalgo®* *fentanyl 37.5 mcg, 62.5 mcg, and 87.5 mcg patches* *hydromorphone ER* *Hysingla ER™* *Kadian® ER* *Morphabond™ ER* *morphine ER cap (generic Avinza®)* *morphine ER cap (generic Kadian®)* *MS Contin®* *Oramorph® SR®* *oxycodone-long acting* *OxyContin®* *oxymorphone ER* *Xartemis™ XR* *Zohydro ER™*	
***Methadone Drugs**		

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	Non-Preferred Agents	SA Criteria
	Dolophine® *Methadose® oral soln & tab* *methadone oral soln & tab*	*Methadone requires the completion of the Clinical SA form **(Methadone SA Form)** unless prescribed for neonatal abstinence syndrome for an infant under the age of one.
***♦ Opioids – Short Acting**		
***Transmucosal Immediate Release Fentanyl**		**LENGTH OF AUTHORIZATIONS:** • Up to 3 months for (includes HIV/AIDS, Chronic back pain, Arthritis, Fibromyalgia, Diabetic neuropathy, Postherpetic Neuralgia). • Up to 6 months for chronic pain (includes Cancer pain, Sickle cell disease, Palliative care, End-of-Life Care, Hospice).
	Fentora® *fentanyl citrate* *Lazanda®* *Subsys®*	
Short-Acting Opioids		***All Short-Acting Opioids (preferred and non-preferred) require the submission of a Clinical SA if prescribed for > 7 days or if more than two 7-day supply prescriptions within 60 days. Refer to combined short/long-acting opioid SA form (Short & Long Acting Opioid SA Form)**
codeine/APAP **hydrocodone/APAP** **hydrocodone/ibuprofen** **hydromorphone** **morphine IR** **oxycodone IR** **oxycodone/APAP** **tramadol HCl 50mg** **tramadol HCl/APAP**	*Abstral®* *Apadaz™* *codeine tab/soln* *butalbital comp with codeine* *butalbital/caffeine/APAP w/codeine* *butorphanol tartrate nasal* *dihydrocodeine/APAP/caffeine* *dihydrocodeine/ASA/caffeine* *hydromorphone liq/supp* *meperidine tab* *morphine supp* *Oxaydo®* *oxycodone/APAP(gen PrimLev™)* *oxycodone conc* *oxycodone oral syringe* *oxycodone/ASA* *oxycodone/ibuprofen* *oxymorphone HCl* *Panlor®* *pentazocine/naloxone* *PrimLev™* *RoxyBond ™* *Seglentis®*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	Non-Preferred Agents	SA Criteria
	tramadol 100 Mg *tramadol soln (AG for Qdolo®)* *Ultracet®* *Ultram®* *Zamicet ®soln*	
♦ Opioid Dependency	CLOSED CLASS	
***buprenorphine SL** **buprenorphine/naloxone tab SL** **Brixadi™** **Suboxone® film** **Sublocade™ SQ** **Kloxxado™ Spray** **naloxone syringe & vial** **naloxone nasal spray** **naloxone nasal spray OTC** **Naloxone Carpuject** **naltrexone tab** **Narcan® Nasal Spray Rx/OTC** **Opvee®** **Rextovy™ Nasal Spray** **Vivitrol®** **Zimhi™**	**buprenorphine/naloxone film SL* **Probuphine® implant* **Zubsolv™* ***Lucemyra®* ***lofexidine*	***Buprenorphine Containing Drugs require submission of Clinical SA. Refer (Oral Buprenorphine SA Form)** **Lucemyra/lofexidine (PDL criteria do not apply) -Member is 18 years of age or older AND -Medication used for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation Limitation: No more than one (14 day) treatment course every 6 months **Quantity Limits** buprenorphine SL tab 2mg — 3/day buprenorphine SL tab 8mg — 2/day buprenorphine/naloxone SL tab 2–0.5mg — 3/day buprenorphine/naloxone SL tab 8–2mg — 3/day buprenorphine/naloxone SL film 2–0.5mg — 3/day buprenorphine/naloxone SL film 4–1mg — 1/day buprenorphine/naloxone SL film 8–2mg — 3/day Suboxone® SL film 2–0.5mg — 3/day Suboxone® SL film 4–1mg — 1/day Suboxone® SL film 8–2mg — 3/day Suboxone® SL film 12–3mg — 2/day Zubsolv™ SL tab 0.7–0.18 mg — 2/day Zubsolv™ SL tab 1.4–0.36mg — 2/day Zubsolv™ SL tab 2.9–0.71mg — 2/day Zubsolv™ SL tab 5.7–1.4mg — 2/day Zubsolv™ SL tab 8.6–2.1mg — 2/day Zubsolv™ SL tab 11.4–2.9mg — 2/day

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)		
Oral NSAIDs		**LENGTH OF AUTHORIZATIONS: 1 year** **Routine PDL edits plus** ***Step edit required for Celebrex® and celecoxib** • History of a trial of a minimum of two (2) different non-COX2 NSAIDs within the past year**; OR** • Concurrent use of anticoagulants (i.e., warfarin, heparin, etc.)**,** methotrexate, oral corticosteroids; **OR** • History of previous GI bleed or conditions associated with GI toxicity risk factors (i.e., PUD, GERD, etc), **OR** • Specific indication for Celebrex® for which preferred drugs are not indicated.
Children's Motrin® susp (OTC) **diclofenac sodium** **ibuprofen cap** **ibuprofen tab (OTC & Rx)** **Infant's ibuprofen drops** **meloxicam tab** **naproxen tab** **naproxen sodium (OTC)** **naproxen EC (Rx)** **sulindac**	*Anaprox® IR & DS®* *Advil®* *Aleve®* *Arthrotec®* *Cataflam®* **Celebrex® & *celecoxib* *Daypro®* *diclofenac potassium* *diclofenac potassium gen Zipsor™* *diclofenac sodium ER* *diclofenac sodium/misoprostol* *diflunisal* *Duexis®* *etodolac IR & SR* *Feldene®* *fenoprofen* *flurbiprofen* *ibuprofen tab chew OTC* *ibuprofen-famotidine (gen Duexis®)* *Indocin® supp* *indomethacin IR, SR & rectal* *ketoprofen IR & ER* *ketorolac* *ketorolac tromethamine (generic Sprix® nasal spray)* *meclofenamate* *mefenamic* *meloxicam susp* *meloxicam (generic Vivlodex™)* *Mobic® susp* *Motrin®* *nabumetone* *Nalfon®*	

	Preferred Agents	Non-Preferred Agents	SA Criteria
		Naprelan® *Naprosyn®* *naproxen CR (generic Naprelan®)* *naproxen-esomeprazole mag (generic Vimovo®)DR* *naproxen sodium (RX)* *naproxen susp* *oxaprozin* *piroxicam* *Ponstel®* *Prevacid Naprapac®* *Sprix® nasal spray* *Tivorbex™* *tolmetin sodium* *Vimovo®* *Vivlodex™* *Voltaren®XR* *Zipsor®* *Zorvolex™*	
	Topical NSAIDs		**LENGTH OF AUTHORIZATIONS: 1 year** **Routine PDL edits plus** **<u>Clinical Criteria for Non-Preferred Topical NSAIDs; *Flector®, diclofenac 2% topical sol, Pennsaid®, Vopac MDS, & Xrylix™ Kit:</u>** • Approval is based on member failing the oral generic of the desired drug and at least one other preferred NSAID (to equal a total of at least two preferred). For example, a member who failed ibuprofen or naproxen will still need to try oral diclofenac for approval of Flector®. • diclofenac 2% topical sol, Pennsaid®, Vopac MDS, and Xrylix™ Kit can only be approved for the FDA approved indication of osteoarthritis of the knee. ***Quantity limit for Flector® and Licart™ patch = 30 patches per RX***
	diclofenac sodium 1% gel **diclofenac sodium 1% gel (OTC)**	**diclofenac 2% topical sol gen Pennsaid®* **Flector® patch (QL)* *Licart™ patch (diclofenac epolamine 0.013gm (QL)* **Pennsaid® top soln, soln pkt & pump* **Vopac MDS* **Voltaren® 1% gel* **Voltaren® 1% gel (OTC)* **XrylixTM Kit*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Antibiotic-Anti-Infective			
	***♦ Antibiotics, Inhaled (QL, AGE) CLOSED CLASS**		
	Bethkis® **Kitabis™ Pak** ****Tobi Podhaler®** ***(SE)*** **tobramycin inhalation neb soln (generic Tobi® inh)**	****Arikayce®** *(amikacin liposome)* *Cayston®* *Tobi® inh neb soln* *tobramycin (generic Bethkis®)* *tobramycin Pak (generic Kitabis™ Pak)*	**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL edits plus** **Tobi Podhaler® • Requires a clinical reason as to why one of the preferred tobramycin inhalation nebulizer solutions cannot be used ****Clinical Criteria for Arikayce®** Duration of Approval: 12 months **Initial Approval Criteria** • Member is ≥ 18 years of age; AND • Diagnosis of Mycobacterium avium complex (MAC) lung disease as determined by the following: o chest radiography or high-resolution computed tomography (HRCT) scan; AND o at least 2 positive sputum cultures; AND o other conditions such as tuberculosis and lung malignancy have been ruled out; AND • Member has failed a multi-drug regimen with a macrolide (clarithromycin or azithromycin), rifampin, and ethambutol. (Failure is defined as continual positive sputum cultures for MAC while adhering to a multi-drug treatment regimen for a minimum duration of 6 months); AND • Member has documented failure or intolerance to aerosolized administration of amikacin solution for injection, including pretreatment with a bronchodilator; AND • Arikayce will be prescribed in conjunction with a multi-drug antimycobacterial regimen *Minimum age for use is 6 years for all tobramycin inhalation nebulizer solution (Bethkis®, Kitabis™ Pak, Tobi® and Tobi Podhaler®) and 7 years for Cayston®. **Quantity Limitations:** Arikayce®= 590 mg/8.4 Ml (28 vials)/28 days Each carton contains a 28-day supply of medication (28 vials) Bethkis® = 224Ml (56 amps)/28 days

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
		Cayston® = 84 Ml (56 amps)/28 days Kitabis™ Pak = 280Ml (56 amps)/28 days Tobi Podhaler® = 224 capsule/28 day Tobi® inhalation neb = 280Ml (56 amps)/28 days tobramycin nebs = 280Ml (56 amps)/28 days
Antifungals, Oral		
fluconazole tab/susp **griseofulvin susp** **nystatin tab/susp** **terbinafine tab**	*Ancobon ®* *Brexafemme®* *clotrimazole (mucous mem)* *Cresemba®* *Diflucan® tab/susp* *flucytosine* *Gris-Peg®* *griseofulvin tab* *griseofulvin ultramicrosize* *itraconazole* *itraconazole soln (generic for Sporanox® soln)* *ketoconazole* *Lamisil ® tab/granules* *Noxafil®* *Noxafil® Powdermix* *posaconazole tab (generic for Noxafil)* *Sporanox® cap/soln* *Tolsura™* *Vfend® tab/susp* **Vivjoa®* *voriconazole tab & powder for susp*	**LENGTH OF AUTHORIZATIONS**: Duration of the prescription (up to 12 months) **Routine PDL edits plus** **Clinical Criteria for all Non-Preferred oral Antifungals. Requires the submission of a Clinical SA. Refer to Antifungal Oral SA Form** ***Clinical Criteria for Vivjoa:** Duration of approval: Date of service • Member is 10 years of age or older; AND • Documentation member has diagnosis of recurrent vulvovaginal candidiasis with ≥3 episodes of vulvovaginal candidiasis (VVC) in a 12-month period; AND • Member is a biological female who is postmenopausal or has another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy); AND • Member has tried and failed or has a contraindication or intolerance to maintenance antifungal therapy with oral fluconazole. Quantity limit: 18 tablets per treatment course
Cephalosporins, Oral		
Second Generation Cephalosporins		**LENGTH OF AUTHORIZATIONS**: Date of service only; no refills. **Routine PDL edits plus** **Clinical Criteria for Non-Preferred Cephalosporins**
cefaclor capsule **cefprozil tab/susp** **cefuroxime tab**	*cefaclor ER* *cefaclor susp* *Ceftin® tab/susp*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Third Generation Cephalosporins		• Infection caused by an organism resistant to preferred drugs, **OR** • A therapeutic failure to no less than a three-day trial of **<u>one preferred cephalosporin</u>**; **OR** • The member is completing a course of therapy with a non-preferred drug initiated in the hospital.
cefdinir cap/susp	*Cedax® cap/susp* *ceftibuten* *cefditoren pivoxil* *cefixime suspension* *cefpodoxime proxetil cap/susp* *Spectracef®* *Suprax® chewable tab/cap/susp*	
Macrolides, Oral		
Macrolides & Ketolides		**<u>LENGTH OF AUTHORIZATIONS</u>**: Date of service only; no refills **Routine PDL edits plus** **<u>Clinical Criteria for Non-Preferred Macrolides and Ketolides</u>** • Infection caused by an organism resistant to preferred drugs, **OR** • A therapeutic failure to no less than a **<u>three-day trial of one preferred drug within the same class</u>**; **OR** • The member is completing a course of therapy with a non-preferred drug which was initiated in the hospital.
azithromycin pack/susp/tab **clarithromycin tab/susp** **E.E.S.® 200 susp** **erythromycin base tab DR** **erythromycin ethylsuccinate 200mg susp** **erythromycin stearate**	*Biaxin® tab* *clarithromycin ER* *Eryped® 200 susp* *Eryped® 400 susp* *Ery-tab®* *E.E.S.® 400 tab* *Erythrocin® Stearate* *erythromycin base cap DR* *erythromycin base tab* *erythromycin ethylsuccinate 400mg tab(Generic E.E.S.® 400)* *PCE®* *Zithromax® pac/tab/susp* *ZMAX® susp*	
Otic		
Ciprodex® **ciprofloxacin/dexamethasone (generic Ciprodex)** **ofloxacin** **neomycin/polymyxin/hc soln/sus**	*Cetraxal®* *Cipro HC®* *ciprofloxacin and fluocinolone acetonide (generic Otovel)* *Otovel*	**<u>LENGTH OF AUTHORIZATIONS:</u>** Date of service only; no refills **Routine PDL edits**

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Quinolones, Oral		
Second Generation Quinolones		**LENGTH OF AUTHORIZATIONS**: Date of service only; no refills **Routine PDL edits plus**: **Clinical Criteria for Non-Preferred Quinolones** • Infection caused by an organism resistant to preferred drugs; **OR** • A therapeutic failure to no less than a **three-day trial of one preferred quinolone**; **OR** • The member is completing a course of therapy with a non-preferred drug initiated in the hospital.
ciprofloxacin susp/tab	*Cipro® IR, XR & susp* *ciprofloxacin ER* *Noroxin®* *ofloxacin*	
Third Generation Quinolones		
levofloxacin tab	*Baxdela™ tab* *Levaquin® tab/susp* *levofloxacin susp* *moxifloxacin*	
Topical Antibiotics		
mupirocin ointment	**Altabax™ (QL)* *Bactroban® cr/ointment* *Centany®* *Centany AT® Kit*	**LENGTH OF AUTHORIZATIONS**: Date of service only; no refills **Routine PDL edits** **Quantity Limit = 15 grams per 34 days*
Vaginal Antibiotics		
Cleocin® Ovules **Clindesse® cr** **metronidazole gel** **Nuvessa™**	*Cleocin® cr* *clindamycin cr* *Metrogel®* *metronidazole gel (generic for Nuvessa™)* *Vandazole™ gel* *Xaciato™ gel*	**LENGTH OF AUTHORIZATIONS**: Date of Service **Routine PDL edits**

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Antivirals		
Hepatitis B Agents **CLOSED CLASS**		
entecavir (generic for Baraclude®) tab	*adefovir dipivoxil (generic for Hepsera®) tab* *Baraclude® (entecavir) soln* *Baraclude® (entecavir) tab* *Epivir HBV® (lamivudine) soln* *lamivudine HBV (generic for Epivir HBV®) tab* **Vemlidy® (tenofovir alafenamide)*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits plus** ***Vemlidy®** ○ Member has a diagnosis of chronic hepatitis B infection; **AND** ○ Member has tried and failed or is intolerant to tenofovir disoproxil fumarate (generic Viread)
***Hepatitis C Agents** **CLOSED CLASS**		
Interferon		**LENGTH OF AUTHORIZATIONS**: ***Non-preferred agents require the submission of a Clinical SA. Preferred agents do not require submission of any SA. Refer to** Hepatitis C Antivirals Non-Preferred SA Form *** Hepatitis C Therapies may filled:** 1. Monthly a. Mavyret™ (28 days supply x 2 months) b. Mavyret™ Pellet packs (28 days supply x 2 months) c. sofosbuvir /velpatasvir (generic Epclusa®) (28 days supply x 3 months) **OR** 2. Full duration of the regimen: a. Mavyret™ (56 days supply) b. Mavyret™ Pellet packs (56 days supply) c. sofosbuvir/velpatasvir (generic Epclusa®) (84 day supply)
	Pegasys® syringe/vial	
***Nucleotide Analog NS5A & NS5B Polymerase Inhibitors & Combinations**		
sofosbuvir /velpatasvir (generic Epclusa®)	*Epclusa®* *Epclusa® Pellet packs* *Sovaldi®* *Vosevi™*	
***NS5A, NS3/4A Inhibitor Combinations**		
Mavyret™ **Mavyret™ Pellet packs**	*Zepatier®*	
***NS5B & Protease Inhibitor Combinations**		
	Harvoni® *ledipasvir/sofosbuvir (generic Harvoni®)*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Herpes Oral		
acyclovir cap/tab/susp **famciclovir** **valacyclovir**	*Famvir®* *Sitavig® buccal tab* *Valtrex®* *Zovirax® tab/susp*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
Herpes Topical		
acyclovir oint **docosanol**	*Abreva OTC®* *acyclovir cr (generic Zovirax cr)* *Denavir®* *penciclovir* *Xerese® cr* *Zovirax® oint* *Zovirax® cr*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
HIV/AIDS CLOSED CLASS		
abacavir tab/soln **abacavir-lamivudine tab** **abacavir-lamivudine-zidov tab** **Apretude** **Aptivus® soln** **atazanavir sulfate cap** **Biktarvy® tab** **Cabenuva** **Cimduo® tab** **Complera® tab** **darunavir** **Delstrigo™ tab** **Descovy® tab** **Dovato® tab** **Edurant® tab** **efavirenz tab** **efavir-emtri-tenof tab** **emtricitabine cap** **emtricitabine-tenofv** **Emtriva™ cap/soln** **Epivir® soln**	*Aptivus® cap* *Atripla® tab* *Combivir® tab* *didanosine cap DR* *efavirenz cap* *efavirenz-lamiv-tenof tab* *Epivir® tab* *Epzicom® tab* *Kaletra® tab/soln* *Lexiva® susp* *Norvir® tab* *Prezista® tab/susp* *Retrovir® syrup* *Reyataz® cap* *stavudine cap* *Trizivir® tab* *Trogarzo® (intraven)* *Viracept® tab* *Viread® tab* *Ziagen® tab*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits** **Quantity limits see list here HIV Quantity Limits**

	Preferred Agents	*Non-Preferred Agents*		*SA Criteria*
	etravirine tab **Evotaz® tab** **fosamprenavir tab/susp** **Fuzeon® Vial** **Genvoya® tab** **Intelence® tab** **Invirase® tab** **Isentress® chew tab/ tab/powder pack** **Juluca® tab** **lamivudine tab/soln** **lamivudine-zidovudine tab** **Lexiva® tab** **lopinavir-ritonavir soln/tab** **Maraviroc** **nevirapine IR tab/ ER tab/susp** **Norvir® powder pack** **Odefsey® tab** **Pifeltro™ tab** **Prezcobix® tab** **Retrovir® cap/vial** **Reyataz® powder pack** **Rilpivirine ER vial** **ritonavir tab/soln** **Rukobia™ ER tab** **Selzentry® tab/soln** **Stribild® tab** **Sunlenca® tab/vial** **Symfi® and Symfi Lo® tab** **Symtuza® tab** **Temixys™ tab** **tenofovir disoproxil fum tab** **Tivicay® tab/tab for susp** **Triumeq® tab** **Triumeq® PD** **Truvada® tab**			

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	Tybost® tab **Viramune® tab** **Viread® powder** **Vocabria** **Ziagen® soln** **zidovudine tab/cap/syrup**		
	Influenza		
	oseltamivir susp/ cap	*Flumadine® tab* *rimantadine* *Relenza Disk®* *Tamiflu® susp/cap* *Xofluza™*	**LENGTH OF AUTHORIZATIONS:** Date of service only **Routine PDL edits**
Blood Modifiers			
	Bile Salts		
	ursodiol cap, tab	**Bylvay™* *Chenodal®* *Cholbam®* *Iqirvo®* ***Livmarli™* *Ocaliva®* *Reltone®* *Urso® & Urso® Forte tab*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits** **Livmarli™ (PDL criteria do not apply) • Must have a confirmed diagnosis of cholestatic pruritus in: ○ Members 3 months of age and older with Alagille syndrome (ALGS) ○ Members 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). * Bylvay™ (PDL criteria do not apply) • Must have a confirmed diagnosis of cholestatic pruritus in: ○ Members 12 months of age and older with Alagille syndrome (ALGS) ○ Members 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
	Colony Stimulating Factors CLOSED CLASS		
	Fulphila	*Fylnetra*	**LENGTH OF AUTHORIZATIONS**:

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	Neupogen Disp Syrin **Neupogen Vial**	*Granix Syringe* *Granix Vial* *Leukine* *Neulasta Kit* *Neulasta Syringe* *Nivestym Syringe* *Nivestym Vial* *Nyvepria* *Releuko Syringe* *Releuko Vial* *Rolvedon Syringe* *Stimufend Syringe* *Udenyca* *Udenyca Autoinjector* *Udenyca Onbody* *Zarxio* *Ziextenzo Syringe*	**Routine PDL edits plus** **♦All Non-Preferred Colony Stimulating Factors require submission of Clinical SA. Refer to: Non-Preferred Colony Stimulating Factors SA Form**
	Hemophilia Treatment CLOSED CLASS		
	Factor VIII Products		**LENGTH OF AUTHORIZATIONS**: N/A All products are preferred without EDITS
	Advate® **Adynovate®** **Afstyla®** **Alphanate®** **Altuviiio™** **Eloctate®** **Esperoct®** **Hemofil-M®** **Humate-P®** **Jivi®** **Koate-DVI®** **Kogenate FS®** **Kovaltry®** **Novoeight®** **Nuwiq®** **Obizur®**		

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Recombinate® **Xyntha® Kit & Solofuse Syr**		
Factor IX Products		
AlphaNine SD® **Alprolix®** **BeneFIX®** **Idelvion®** **Ixinity®** **Profilnine SD®** **Rebinyn®** **Rixubis®**		
Factor VIIa & Activated Prothrombin Complex Concentrate		
Feiba NF® **NovoSeven RT®** **Sevenfact®**		
Factor IXa and Factor X Directed Antibody		
Hemlibra®		
Factor X and Factor XIII Products		
Coagadex® **Corifact® Kit** **Tretten®**		
Prothrombin Complex Concentrate		
Balfaxar®		
Von Willebrand		
Vonvendi® **Wilate®**		
Phosphate Binders		

	Preferred Agents	Non-Preferred Agents	SA Criteria
	calcium acetate 667mg cap **calcium acetate 668 mg** **sevelamer carbonate tab**	*Auryxia™* *calcium acetate 667mg tab* *Calphron* *Eliphos* *Fosrenol® chewable tab* *lanthanum carbonate chewable tab* *Phoslyra® powder, tab* *Renagel®* *Renvela®* *sevelamer carbonate powder packet* *sevelamer HCL (gen Renagel)* *Velphoro® chewable tab* *Xphozah™*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
	Sickle Cell CLOSED CLASS		
	Droxia **Endari** ****Siklos**	*Adakveo IV* *l-glutamine(generic Endari)*	*Non-preferred agents and **Siklos® (if 18 years of age and older) require the submission of a Clinical SA. Preferred agents do not require submission of any SA. Refer to **Sickle Cell SA Form** ****Clinical Criteria for Siklos (hydroxyurea):** • Member must be 2-17 years old
Bone Resorption Suppression and Related Agents			
	Bisphosphonates		
	alendronate tab **ibandronate**	*Actonel®* *alendronate soln* *Atelvia DR®* *Boniva®* *Binosto™* *etidronate* *Fosamax®tab & Fosamax®plusD* *risedronate DR*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	Calcitonins		
	calcitonin-salmon nasal	~~*Miacalcin® spray*~~ ~~*calcitonin-salmon (gen Miacalcin®)*~~	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
	Others		
	raloxifene	*Evista®* **Forteo®* *teriparatide* **Tymlos™*	**LENGTH OF AUTHORIZATIONS**: Initial approval will be for 1 year **Routine PDL edits for Evista®** ***♦ Clinical SA must be completed for (Forteo® OR Tymlos™ SA Form)**
Cardiac			
	Anticoagulants **CLOSED CLASS**		
	Low Molecular Weight Heparin includes FactorXA Inhibitor		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
	enoxaparin (generic Lovenox®)	*Arixtra®* *fondaparinux* *Fragmin® syringe & vial* *Lovenox®*	
	Oral Anticoagulants		***Clinicial Criteria for Savaysa™** • Diagnosis of: Non-valvular Atrial Fibrillation, **OR** • Deep vein thrombosis, **OR** • Pulmonary embolism; **AND** • Documentation that CrCl is NOT ≥ 95mL/min calculated by Cockcroft-Gault equation
	Eliquis™ **Eliquis™ Dose Pack** **Jantoven ®** **Pradaxa®** **warfarin** **Xarelto® & Starter Pack, susp**	*dabigatran* *Pradaxa® Pellet Pack* **Savaysa™*	
	Antihypertensive Agents		
	ACE Inhibitors		**LENGTH OF AUTHORIZATIONS: 1 year** **Routine PDL edits**
	benazepril **enalapril** **lisinopril** **ramipril** **quinapril**	*Accupril®* *Altace®* *captopril* *Epaned™ soln* *enalapril soln*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	fosinopril *Lotensin®* *Mavik®* *moexipril* *Monopril®* *perindopril* *Qbrelis™* *trandolapril* *Univasc®* *Vasotec®* *Zestril®*	
ACE Inhibitors + Calcium Channel Blocker Combinations		
amlodipine/benazepril	*Lotrel®* *Tarka®* *trandolapril-verapamil ER*	
ACE Inhibitors + Diuretic Combinations		
benazepril/HCTZ **lisinopril/HCTZ** **enalapril/HCTZ**	*Accuretic®* *captopril/HCTZ* *fosinopril/HCTZ* *Lotensin HCT®* *moexipril/HCTZ* *quinapril /HCTZ* *quinapril-HCTZ (gen Accuretic)* *Vaseretic®* *Zestoretic®*	
Angiotensin Receptor Blockers		**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL edits plus** *Quantity Limit = 2 per day for Entresto™*
***Entresto™ (QL)** **irbesartan** **losartan** **olmesartan** **valsartan**	*Atacand®* *Avapro®* *Benicar®* *candesartan* *Cozaar®*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	Diovan® *Edarbi®* ***Entresto Sprinkle™* *eprosartan mesylate* *Micardis®* *Teveten®* *valsartan solution*	****Entresto Sprinkle capsule:** • The member is intolerant to solid oral dosage forms
Angiotensin Receptor Blockers + Calcium Channel Blocker Combinations		
amlodipine/olmesartan **amlodipine/valsartan**	*Azor®* *amlodipine/olmesartan/HCTZ* *amlodipine/valsartan/HCTZ* *Exforge® & Exforge® HCT* *Tribenzor®*	
Angiotensin Receptor Blockers + Diuretic Combinations		
irbesartan/HCTZ **losartan/HCTZ** **olmesartan/HCTZ** **valsartan/HCTZ**	*Atacand HCT®* *Avalide®* *Benicar HCT®* *candesartan/HCTZ* *Diovan HCT®* *Edarbyclor®* *Hyzaar®* *Micardis HCT®* *telmisartan/HCTZ* *Teveten HCT®*	
Beta Blockers		***Clinical Criteria for Hemangeol™** • Diagnosis of proliferating infantile hemangioma requiring systemic therapy
atenolol **bisoprolol** **carvedilol** **labetalol** **metoprolol tartrate** **metoprolol succinate** **propranolol tab & ER/soln**	*acebutolol* *Betapace®IR & AF®* *betaxolol* *Carvedilol ER* *Coreg® IR & CR®* *Corgard®* **Hemangeol™*	

Preferred Agents	Non-Preferred Agents	SA Criteria
Sorine® **sotalol AF** **sotalol HCL**	*Inderal® XL* *Innopran® XL* *Kapspargo™ Sprinkle* *Levatol®* *Lopressor®* *nebivolol* *nadolol* *pindolol* *propranolol LA* *Sectral®* *Sotylize ™* *Tenormin®* *timolol maleate* *Toprol XL®* *Trandate®* *Zebeta®*	
Beta Blockers + Diuretic Combinations		
atenolol/chlorthalidone **bisoprolol/HCTZ**	*Corzide®* *Dutoprol®* *Lopressor HCT®* *metoprolol/HCTZ* *nadolol/bendroflumethiazide* *propranolol/HCTZ* *Tenoretic®*	
Calcium Channel Blockers –Dihydropyridine		
Afeditab CR® **amlodipine** **Nifedical XL®** **nifedipine** **nifedipine ER**	*Adalat CC®* *Conjupri®* *Consensi® (amlodipine/celecoxib)* *felodipine ER* *isradipine* *Katerzia™oral suspension* *levamlodipine (generic Conjupri®)* *nisoldipine*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	nicardipine *Norliqva®* *Norvasc®* *Procardia XL®* *Sular®*	
Calcium Channel Blockers- Non-Dihydropyridine		
Cartia XT® **diltiazem IR, ER q12hr & 24hr** **Taztia XT®** **verapamil tab IR & ER**	*Calan® IR & SR* *Cardizem® IR, CD & LA* *Isoptin SR®* *diltiazem LA* *Matzim LA* *Tiazac®* *verapamil 360 cap* *verapamil ER cap* *Verelan® & Verelan PM®*	
Direct Renin Inhibitors (includes combination)		
	aliskiren 150 & 300mg (generic for Tekturna) *Tekamlo®* *Tekturna®* *Tekturna HCT®* *Twynsta®* *telmisartan/amlodipine*	
Lipotropics		
Bile Acid Sequestrants		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
cholestyramine powder reg & light **colestipol tab** **Prevalite®**	*Colestid® packet/tab* *colesevelam tab and Pkt (generic Welchol)* *colestipol HCl granules*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	Questran® powder/powder Light *Welchol® pack, tab*	
Cholesterol Absorption Inhibitor (CAI) and /or ACL Inhibitor (adenosine triphosphate citrate lyase)		**Routine PDL edits plus** ♦ **Clinical criteria Nexletol™ or Nexlizet™** **Initial Approval Criteria** • Member is ≥ 18 years of age; AND • Member has diagnosis of heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD); AND • Member has failed to achieve a target LDL-C despite physician attestation that the member is adherent to maximally tolerated doses of statins prior to the lipid panel demonstrating suboptimal reduction; AND • Member can be classified into ONE of the following risk factor groups: o Extremely high risk ASCVD: (defined as extensive or active burden of ASCVD, or ASCVD with extremely high burden of adverse or poorly controlled risk cardio-metabolic risk factors including HeFH or severe hypercholesterolemia [SH] LDL-C > 220 mg/dl) with an LDL-C ≥ 70 mg/dL; OR o Very high risk ASCVD: (defined as less extensive ASCVD and poorly controlled cardiometabolic risk factors) with an LDL-C ≥ 100 mg/dL; OR o High risk ASCVD: (defined as either less extensive ASCVD and well-controlled risk factors or primary prevention HeFH or SH >220 mg/dl with poorly controlled risk factors) with LDL-C ≥ 130 mg/dL; AND • Therapy will be used in conjunction with maximally tolerated doses of a statin; AND • Therapy will not be used with concurrent doses of simvastatin > 20 mg or pravastatin > 40mg; **Renewal Criteria** • Laboratory analyses demonstrate a reduction in LDL-C when compared to the baseline values (prior to initiating bempedoic acid or bempedoic acid/ezetimibe); AND • Member has shown continued adherence to maximally tolerated statin dosage
ezetimibe	*Nexletol® (bempedoic acid)* *Nexlizet® (bempedoic acid/ ezetimibe)* *Zetia®*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Fibric Acid Derivatives		
fenofibrate (*generic Tricor® 48mg 145mg)* **gemfibrozil**	*Antara®* *fenofibrate (generics for Antara®, Fenoglide® & Lipofen®)* *fenofibrate (generics for Triglide®)* *fenofibric acid* *Fenoglide®* *Fibricor®* *Lipofen®* *Lofibra®* *Lopid®* *Tricor®* *Triglide®* *Trilipix™*	
HMG CoA Reductase Inhibitors and Combo (High Potency Statins)		
atorvastatin **rosuvastatin** **simvastatin**	*Atorvaliq®* *amlodipine/atorvastatin* *Caduet®* *Crestor®* *Ezallor Sprinkle (rosuvastatin)* *Lipitor®* *Livalo®* *pitavastatin calcium (generic Livalo®)* *rosuvastatin-ezetimibe* *simvastatin soln (generic Flolipid)* *simvastatin/ezetimibe* *Vytorin®* *Zocor®* *Zypitamag ™*	
HMG CoA Reductase Inhibitors and Combinations (Statins)		
lovastatin **pravastatin**	*Altoprev®* *fluvastatin*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	Non-Preferred Agents	SA Criteria
	Lescol®and Lescol XL® *Mevacor®* *Pravachol®*	
Microsomal Triglyceride Transfer Protein Inhibitor		***♦ Clinical Criteria for Juxtapid™. Refer to Juxtapid™ SA Fax Form**
	**Juxtapid ™*	
Niacin Derivatives		
niacin ER	*Niaspan®* *Niacor®*	
Omega 3 Fatty Acid Agent		*****♦ Clinical Criteria for Lovaza® and omega-3 acid ethyl esters** • Step edit requires trial and failure of any other lipotropic; **OR** • Documented high triglycerides of ≥ 500 mg/dL. **LENGTH OF AUTHORIZATIONS**: Three months for initial approval; six months for renewal ***♦ ALL PCSK9 Inhibitors require the submission of a Clinical SA. Refer to Lipotropics, Other SA Form**
icosapent ethyl (gen Vascepa®) ****omega-3 acid ethyl esters (ST)*** **Omega-3 OTC**	****Lovaza® (ST)*	
***Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors**		
	Leqvio® *Praluent®* *Repatha®*	
Platelet Inhibitors		
Brilinta® **clopidogrel** **dipyridamole** **prasugrel (generic Effient®)**	**Aggrenox®* **ASA/dipyridamole* ***ASA/omeprazole (generic Yosprala®)* ***Durlaza ER™* *Effient®* *Persantine®* *Plavix®* ***Yosprala® Tab* ****Zontivity™*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits plus** **Clinical Criteria for Select Non-Preferred Platelet Inhibitors** ***Aggrenox® & ASA/dipyridamole** • Aspirin and dipyridamole are covered as separate drugs without SA; clinical reason as to why the individual drugs cannot be used separately. ****Durlaza ER™ & *Yosprala® Tab** • Aspirin is covered without SA; clinical reason as to why aspirin cannot be used. ***** Zontivity™** • Diagnosis of MI (myocardial infarction) or PAD (peripheral arterial disease); **AND** • Members must not have a history of stroke, TIA, ICH, GI bleed and peptic ulcer; **AND** • Must have concomitant therapy with clopidogrel, unless member has a contraindication to clopidogrel in which case member must have concomitant therapy with aspirin; **AND**

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
			• Member is 18 years of age or older; **AND** • Prescribed by or in consultation with a cardiologist.
	***Pulmonary Arterial Hypertension Agents**		
	Activin Signaling Inhibitor		**LENGTH OF AUTHORIZATIONS: 1 year** **Routine PDL edits for all Pulmonary Arterial Hypertension Agents**
		Winrevair™	
	Inhaled Prostacyclin Analogues		
	Ventavis®	*Tyvaso®* *Tyvaso DPI™ (treprostinil)*	
	Oral Endothelin Receptor Antagonist		
	ambrisentan (generic Letairis) 5 & 10mg **Tracleer® tab**	*bosentan (generic Tracleer®)* *Letairis® 5 & 10 mg* *Opsumit®* *Tracleer® susp*	
	***Phosphodiesterase 5 Inhibitors (PDE-5)**		**Routine PDL edits plus** ***♦ Clinical Criteria for all preferred and non-preferred PDE-5 and PDE-5 inhibitor combinations** • Diagnosis of pulmonary hypertension in members >18 years is required (≥1 years oral Revatio® only); **AND** • The prescriber must be a pulmonary specialist or cardiologist; **AND** • Must have a rationale for not taking the sildenafil tab to receive a SA for injectable Revatio®
	Alyq (tadalafil) **sildenafil tab/susp** **tadalafil(generic Adcirca®)**	*Adcirca®* *Liqrev®* *Revatio® tab/inj/susp* *Tadliq® Suspension*	
	***Phosphodiesterase 5 Inhibitors (PDE-5) Combinations**		
		Opsynvi	
	Prostacyclin Vasodilator and Receptor Agonist		
		Orenitram™ *Orenitram™ titration kit* *Uptravi®*	
	Soluble Guanylate Cyclase Stimulators		
		Adempas®	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Central Nervous System			
Alzheimer's Agents			
Cholinesterase Inhibitors			**LENGTH OF AUTHORIZATIONS**: Length of prescription (up to 3 months) **Routine PDL edits**
	donepezil OTD & tab **rivastigmine (transderm)**	*Adlarity®* *Aricept® ODT, tab* *Exelon® cap &Exelon® (transderm)* *galantamine IR, ER tab/soln* *Namzaric® (donepezil/memantine)* *Razadyne® IR, ER* *rivastigmine cap*	
NMDA Receptor Antagonist			
	memantine tab	*memantine Dose Pack, soln* *memantine ER* *Namenda® Dose Pack/tab* *Namenda® tab*	
Anticonvulsants **CLOSED CLASS**			
Barbiturates			**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL**
	phenobarbital elixir/tab **primidone** **Sezaby**	*Mysoline®*	
Benzodiazepines			
	clobazam tab/susp **clonazepam tab** **Diastat® rectal** **Diastat® AcuDial™ rectal** **diazepam rectal & Device rectal** **Nayzilam®** **Valtoco® Nasal**	*clonazepam ODT* *clorazepate* *Klonopin Tab* *Libervant ™* *Onfi®susp/tab* *Sympazan ™ (clobazam)* *Tranxene®*	
Cannabidiol			
	***Epidioex® (cannabidiol)**		***♦ Clinical Criteria for Epidiolex®** (reviewed electronically, AutoPA) Duration of Approval: 1 year

Preferred Agents	Non-Preferred Agents	SA Criteria
		• Member must be ≥ 1 years of age; AND • Member has been diagnosed with: ○ Epilepsy and recurrent seizures including Lennox-Gastaut syndrome, ○ Dravet syndrome, or tuberous sclerosis complex
Carbamazepine Derivatives		
carbamazepine chewable tab/susp/tab **carbamazepine XR** **Carbatrol®** **Epitol** **oxcarbazepine tab** **Tegretol®XR** **Trileptal® susp**	*Aptiom®* *carbamazepine ER* *carbamazepine XR (authorized generic only)* *Equetro® cap* *Oxtellar™ XR* *oxcarbazepine susp* *oxcarbazepine ER (generic Oxtellar XR)* *Tegretol® susp/tab* *Trileptal®tab*	
Hydantoins		
Dilantin 30mg **phenytoin cap/chew tab/ susp** **phenytoin ext cap**	*Dilantin® cap & Infatab, susp* *Peganone®* *Phenytek®*	
Succinimides		
ethosuximide cap/syrup	*Celontin®* *Zarontin® cap/syrup*	
Valproic Acid and Derivatives		
Depakote® sprinkle **divalproex tab** **divalproex ER** **valproic acid cap, soln**	*Depakote® ER* *divalproex sprinkle*	
Other Anticonvulsants		
lacosamide soln/tab (gen Vimpat®) **lamotrigine tab** **lamotrigine chew tab** **lamotrigine XR**	*Banzel® susp/tab* *Briviact®* tab/soln *Diacomit®* cap/powder pack *Elepsia®XR tab* *Eprontia ™*	*♦ **Clinical Criteria for Fintepla®** • Member is at least two years of age or older; AND • Member must have a diagnosis of Dravet syndrome or Lennox-Gastaut syndrome

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
levetiracetam soln/tab **levetiracetam ER** **roweepra (generic levetiracetam)** **subvenite tab (generic lamotrigine)** **topiramate tab/sprinkle cap** **zonisamide cap**	*felbamate susp/tab* *Felbatol®* ~~*susp*~~*/tab* ** Fintepla®* *Fycompa® susp/tab* *Keppra® soln/tab* *Keppra® XR* *lacosamide solution unit dose* *Lamictal® XR & XR dose pk* *Lamictal® tab/dose pk* *Lamictal® ODT* *Lamictal® ODT dose pk* *lamotrigine tab dose pk* *lamotrigine ODT* *lamotrigine ODT dose pk* *Motpoly XR™* *rufinamide susp/tab (generic Banzel®)* *Qudexy™ XR* *Sabril® powder pack/tab* *Spritam®* *subvenite dose pk* *tiagabine* *Topamax® tab/sprinkle* *topiramate ER cap* *Trokendi™ XR* *vigabatrin tab/ powder pack (generic Sabril®)* *Vigafyde™* *Vimpat® soln/tab* *Xcopri®* *Zonisade™ Solution* ***Ztalmy®*	** ♦ **Clinical Criteria for Ztalmy:** • Initial: ○ Member is two years of age or older; AND ○ Documented diagnosis of cyclin-dependent kinase-like 5 deficiency disorder AND ○ Documentation that seizures have been inadequately controlled by a trial of at least 2 antiepileptic drugs (e.g., clobazam, valproate, lamotrigine, levetiracetam, topiramate, felbamate, vigabatrin) or member has labeled contraindications to other antiepileptic drugs • Renewal: ○ Documentation of positive clinical response as demonstrated by low disease activity and/or improvements in the condition's signs and symptoms (e.g., reduced seizure activity, frequency, and/or duration) • Prescriber Requirements: Prescribed by or in consultation with a neurologist, geneticist, or physician who specialized in treatment of epileptic disorders
Antidepressants		
Other		**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL edits**
bupropion IR, SR &XL	*Aplenzin®* *Auvelity™*	

Preferred Agents	Non-Preferred Agents	SA Criteria
desvenlafaxine ER tab (generic for Pristiq®) **mirtazapine ODT/tab** **trazodone tab** **venlafaxine IR tab & ER cap** **vilazodone tab**	*Brintellix®* *bupropion XL (gen Forfivo® XL)* *desvenlafaxine ER tab (gen Khedezla™)* *Effexor® XR* *Emsam® transdermal* *Fetzima®* *Forfivo® XL* *Khedezla™* *Marplan®* *Nardil®* *nefazodone* *Parnate®* *phenelzine* *Pristiq®* *Remeron® ODT/tab* *tranylcypromine sulfate* *Trintellix* *venlafaxine ER tab* *Viibryd®dose pk* *Viibryd® tab* *Wellbutrin® IR, SR & XL* **Zurzuvae™*	***♦ Zurzuvae criteria (PDL criteria do not apply)** • Initial Criteria: • Member is ≥ 18 years of age; AND • Member has a diagnosis of postpartum depression (PPD) based on Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for a major depressive episode (DSM-5); AND • Member is not currently pregnant and is using effective contraception LENGTH OF AUTHORIZATIONS: 14 days Renewal Criteria: Not applicable Quantity limit: 28 capsules per 14 days
SSRI		
citalopram soln/tab **escitalopram tab** **fluoxetine cap/soln** **fluvoxamine tab** **paroxetine tab** **sertraline conc, soln, tab**	*Brisdelle®* *Celexa® tab* *citalopram HBR 30mg* *escitalopram soln* *fluoxetine DR cap/tab* *fluvoxamine ER* *Lexapro® tab* *Luvox® CR* *paroxetine CR* *paroxetine susp* *Paxil® tab/susp & Paxil® CR* *Pexeva®*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	Prozac® cap/weekly *Sarafem®* *sertraline cap* *Zoloft® conc/tab*	
Antimigraine Agents		
sumatriptan succinate tab **cartridge/vial/pen** **Imitrex® nasal** **rizatriptan tab/MLT**	*almotriptan* *Alsuma®* *Amerge®* *Axert®* *Cambia®* *eletriptan (generic Relpax®)* *Frova®* *frovatriptan (generic Frova®)* *Imitrex® cartridge/pen/tab/vial* *Maxalt® tab & MLT* *Migranow™ Kit* *naratriptan* *Onzetra™ Xsail™* *Relpax®* *sumatriptan KITS* *Sumavel® Dosepro* *sumatriptan/nap (gen Treximet®)* *Tosymra* *Treximet®* *Zembrace ™ SymTouch ™* *zolmitriptan nasal* *Zomig® tab/nasal spray/ZMT*	**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL edit**
Antimigraine Agents, Others **CLOSED CLASS** **Calcitonin Gene-related Peptide Antagonist (CGRP)**		**Routine PDL edits plus** ***♦ All CGRPs require the submission of a Clinical SA. Refer to fax form Antimigraine Agents, Others SA Form** ****Vyepti SA Form**
Preventive Treatment		**Preferred Agents *step edit required**

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Aimovig™ **Ajovy® Autoinjector & Syringe** **Ajovy Autoinjector 3-Pk** **Emgality™ Syringe** **Emgality™ Pen** **Nurtec™ ODT** **Qulipta™**	*Emgality™ 100MG Syringe* ***Vyepti®*	**Quantity limit for preventive treatment** Aimovig™ = 70 mg/mL autoinjector = 1 mL or 140 mg/mL autoinjector = 1 mL per 30 days Ajovy® = 1 Injection: 225 mg/1.5 mL single-dose prefilled autoinjector per 30 days. Ajovy 3 pack = one 3 pack per 90 days Emgality™ = 120 mg/mL pen and syringe = 1 mL per 30 days 100mg/1 mL syringe = 3 mL per 30 days (Episodic cluster headache treatment) Nurtec® ODT = 16 tabs per 30 days Qulipta™ = 1 tab per day
Acute treatment of migraine		
Nurtec™ ODT **Ubrelvy®**	*Reyvow®* *Zavzpret™*	**Quantity limit for acute treatment** Nurtec® ODT = 16 tabs per 30 days Reyvow® = 50mg or 100mg - 8 tabs per strength per 30 days Ubrelvy® = 50mg or 100mg can have up to 16 tabs per strength per 30 days
Antipsychotics *(AGE) **CLOSED CLASS**		
Atypical		**LENGTH OF AUTHORIZATIONS: 1 year or 6 months for members < 18 yrs** **Routine PDL edits plus** ***♦ ALL antipsychotics for children 0 to 17 years of age (preferred and non-preferred) require the submission of a Clinical SA. Refer to (Antipsychotics In Children Less Than 18 Years SA Form)** ****Clinical Criteria Nuplazid™** • Indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. *Quantity Limit Nuplazid™ = 2 per day* *****♦ Clinical Criteria for Abilify Mycite®** **Initial Approval Criteria: For Three months SA** Member must: • Be ≥ 18 years of age; AND • Have tolerability to oral aripiprazole with suboptimal effects (as assessed by prescriber) that may be due to adherence problems; AND
aripiprazole tab **clozapine tab** **lurasidone** **olanzapine ODT, tab, IM** **quetiapine fumarate ER** **quetiapine tab** **risperidone ODT/soln/tab** **Vraylar™** **ziprasidone cap**	*Abilify® tab/IM inj* ****Abilify Mycite®(with sensor)* ***aripiprazole ODT, soln* *asenapine (generic for Saphris®)* *Caplyta Capsule™* *Clozaril®* *clozapine ODT* *Fanapt® tab & titration pk* *Fazaclo®* ***Geodon® tab, IM* *Invega®* *Latuda®* *Lybalvi®* ***Nuplazid™ tab, cap (QL)* ***olanzapine/fluoxetine* *paliperidone ER* *quetiapine fumarate ER (authorized generic only)* *Rexulti® tab* *Risperdal® ODT/soln/tab*	

	Preferred Agents	Non-Preferred Agents	SA Criteria
		Saphris® *Secuado®Patch* *Seroquel® IR* *Seroquel® XR* *Versacloz™* *ziprasidone IM (gen Geodon®)* *Zyprexa® tab/IM/Zydis*	• Have a smart phone compatible with the device; AND • Give consent to a healthcare provider and caregiver (if applicable) to monitor the portal; AND • There is a documented intervention by prescriber if nonadherence is detected **Renewal Criteria: Every 3 Months Reevaluate** • Member must: • Continue to meet initial criteria; AND • Have prescriber attestation that member benefited from therapy; AND • Have prescriber attestation that there is a continued need for device (e.g., continued suboptimal effects and/or compliance); AND • Have a healthcare provider and caregiver (if applicable) agree to continue to monitor device; AND • Not have worsened target symptoms; AND • Not have had any treatment-limited adverse effects (e.g., hypersensitivity, suicidality, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, pathological gambling and other compulsive behaviors, orthostatic hypotension, falls, seizures, cognitive and motor impairment, dysphagia, disruption in body temperature regulation, and leukopenia, neutropenia, and agranulocytosis); AND • Have a healthcare provider state reason why the member cannot use long-acting injectable atypical antipsychotic if there is continued nonadherence.
	Atypical, Long-Acting Injectable		**LENGTH OF AUTHORIZATIONS:** **1 year**
	Abilify Asimtufii® **Abilify Maintena®** **Aristada®** **Aristada® Initio** **Invega Hafyera™, Sustenna®** **&Trinza®** **Perseris™** **Risperdal Consta®** **Uzedy™**	*Rykindo™* *Zyprexa® Relprevv™*	**Routine PDL edits**
	Typical		**LENGTH OF AUTHORIZATIONS:** **1 year**

Preferred Agents	Non-Preferred Agents	SA Criteria
amitriptyline/perphenazine **chlorpromazine** **fluphenazine elixir/soln/tab** **fluphenazine decanoate** **haloperidol decanoate** **haloperidol lactate conc** **haloperidol tab** **loxapine** **perphenazine** **trifluoperazine** **thiothixene** **thioridazine**	*Adasuve®* *Haldol decanoate (injection)* *pimozide* *Moban®* *molindone*	**Routine PDL edits**
Duchenne Muscular Dystrophy CLOSED CLASS		
****Emflaza**	***Agamree* *Amondys-45* ***deflazacort* ***Duvyzat* *Exondys-51* *Viltepso* *Vyondys-53*	**LENGTH OF AUTHORIZATIONS:** **1 year** ****Clinical Criteria for oral Duchenne Muscular Dystrophy agents** • Member is 2 years of age or older Agamree®, Emflaza™ and deflazacort • Member is 6 years of age or older for Duvyzat™ • Member has a diagnosis of Duchenne Muscular Dystrophy (DMD) • For all oral agents, the member has tried and failed or is intolerant to prednisone or prednisolone • For non-preferred agents, the member has tried and failed or is intolerant to Emflaza™ **Routine PDL edits plus** **All Antisense Oligonucleotides require submission of Clinical SA.** Refer to: Antisense Oligonucleotides SA Form
***Movement Disorders CLOSED CLASS**		

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Austedo® tab **Austedo XR® tab** **Austedo XR® titration pack** **Ingrezza® cap** **Ingrezza® Sprinkle** **Ingrezza® Initiation Pack** **tetrabenazine tab (generic Xenazine®)**	*Xenazine® tab*	**LENGTH OF AUTHORIZATIONS:** **1 year** ***Clinical Criteria for Movement Disorders** • Diagnoses of Tardive Dyskinesia or Huntington's disease • Prescribed by or in consult with a neurologist or psychiatrist • Quantity limit o 4 tabs/day Austedo® o 1 tab per day Austedo XR® o 42 tablets per 365 Austedo XR® titration pack o 1 cap/day Ingrezza®/Ingrezza Sprinkle® o 4 tabs/day Xenazine®
Neuropathic Pain		
capsaicin OTC topical **duloxetine 20, 30 & 60 mg (generic for Cymbalta®)** **gabapentin cap/tab/soln** **lidocaine 5% patch** **pregabalin cap**	*Cymbalta®* *Dermacinrx® PHN Pak™ Kit* *Drizalma™ Sprinkle* *duloxetine 40 mg (generic Irenka™)* *gabapentin ER* *Gralise™ (gabapentin, ER)* *Horizant ™ (gabapentin enacarbil ER)* *Irenka™* *Lidoderm® patch* *LidoPure Patch* *Lyrica® /CR/ soln* *Neurontin® cap/tab/soln* *pregabalin soln, ER* *Qutenza Kit® (capsaicin)* *Savella™ & Savella™ Dose Pak* *Zilacaine Patch* *Ztlido™ 1.8% (lidocaine topical system)*	**LENGTH OF AUTHORIZATIONS**: **1 year** **Routine PDL edits plus** **Criteria for Lyrica solution:** − If diagnosis is epilepsy/seizures, member must have a problem swallowing tabs/capsules AND clinical reason why at least TWO preferred seizure medications cannot be used. − For other diagnoses, member must have a problem swallowing tabs/capsules AND routine PDL • If Lyrica CR is requested, routine PDL applies. Note – This is NOT indicated for epilepsy/seizures.
Non-Ergot Dopamine Receptor Agonist		
pramipexole **ropinirole HCl**	*Mirapex® IR & ER* *Neupro®* *pramipexole ER*	**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL edits**

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	Requip® XR *ropinirole HCl ER*	
Sedatives / Hypnotics		
temazepam 15 & 30 mg	*estazolam* *flurazepam* *Halcion®* *quazepam 15 mg* *Restoril®* *temazepam 7.5 mg & 22.5 mg* *triazolam*	**LENGTH OF AUTHORIZATIONS**: Length of the prescription (up to 3 months) **Routine PDL edits**
Sedatives / Hypnotics (Non-Benzodiazepine)		
eszopiclone **zaleplon** **zolpidem**	*Ambien®IR & CR* *Belsomra®* *Dayvigo™* *doxepin (generic for Silenor®)* *Edluar™* **Hetlioz®* ***Hetlioz™ LQ* *Intermezzo®* *Lunesta®* *Quviviq™* *Rozerem®* *Silenor®* *Sonata®* *tasimelteon* *zolpidem CR* *zolpidem (generic Intermezzo®)* *zolpidem tartrate capsule*	**LENGTH OF AUTHORIZATIONS**: 6 months. **For Renewal -** must document therapeutic benefit and confirm compliance **Routine PDL edits plus** *♦ **Clinical Criteria for Hetlioz® and tasimelteon** • For the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24), **AND** • Member must be age 16 years of age or older. • Quantity limit = 1 capsule per day. **♦ **Clinical Criteria for Hetlioz™ LQ oral suspension** • For the treatment Nighttime sleep disturbances in SMS in pediatric members **AND** • Member must be 3 years to 15 years of age.
Skeletal Muscle Relaxants		
baclofen **chlorzoxazone** **cyclobenzaprine HCL** **dantrolene sodium** **methocarbamol** **tizanidine tab**	*Amrix®* *baclofen soln* *baclofen susp (gen Fleqsuvy™)* **carisoprodol* **carisoprodol/ASA* **carisoprodol/ASA/codeine*	**LENGTH OF AUTHORIZATIONS:** • 1 year for chronic conditions • Duration of prescription (up to 3 months) for acute conditions **Routine PDL edits plus**

Preferred Agents	Non-Preferred Agents	SA Criteria
	cyclobenzaprine ER *Dantrium®* *Fexmid®* *Fleqsuvy™* *Lorzone®* *Lyvispah™* *metaxalone* *orphenadrine citrate* *orphenadrine/ASA/caffeine* *Ozobax® DS* *Parafon Forte® DSC* *Robaxin®* *Skelaxin®* **Soma®* *tizanidine cap* *Zanaflex®*	*♦ **Clinical Criteria for Carisoprodol Drugs** • Member is at least 16 years old • Only approve for ACUTE, painful musculoskeletal conditions. • Length of Authorization: One month per every 6 months for carisoprodol drugs • Quantity limit = 4 tablets per day
Smoking Cessation		
bupropion SR **Chantix®** **Chantix® DS PK** **nicotine gum/lozenge/patch** **varenicline**	*Nicoderm CQ® Patch* *Nicorette® Gum/Lozenges* *Nicotrol® Inhaler & NS* *Zyban®*	**LENGTH OF AUTHORIZATIONS:** 6 months **Routine PDL edits**
***Stimulants/ADHD Medications** *(AGE)* **CLOSED CLASS**		
Amphetamine Drugs		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits** *♦ All stimulants (preferred and non-preferred) require the submission of Clinical SA if prescribed for a child less than four or an adult eighteen years and older. Refer to Stimulant SA form (Stimulant/ADHD Medications SA Form) **This does not include nonstimulant agents such as atomoxetine (generic for Strattera®,) clonidine ER, guanfacine ER or others** ***Clinical Criteria for Vyvanse® chewable tab**
amphetamine salts combo *(generic for Adderall IR)* **amphetamine salts combo XR** *(generic for Adderall XR)* **dextroamphetamine tab** *(generic for Dexedrine)* **dextroamphetamine cap SR** *(generic for Dexdrine Spansule)*	*Adderall® IR (amphetamine salts combo)* *Adderall®XR* *Adzenys XR ODT™* *Adzenys ER™ susp* *Adzenys® ER* *amphetamine sulfate (generic Evekeo®)* *amphetamine susp (generic Adzenys ER™ susp)*	

Preferred Agents	Non-Preferred Agents	SA Criteria
Vyvanse® capsule (lisdexamfetamine)	*Desoxyn®* *Dexedrine®* *dextroamphetamine soln* *Dyanavel® XR susp* *Evekeo®* *lisdexamfetamine(generic Vyvanse®)* *methamphetamine* *Mydayis ER™* *Procentra® soln* *Vyvanse® chewable tab* *Xelstrym™* *Zenzedi™*	• Member must have tried and failed methylphenidate solution
Methylphenidate Drugs		
All methylphenidate IR generic **methylphenidate soln** **Concerta®** **Daytrana® Transdermal** **dexmethylphenidate IR** **dexmethylphenidate XR**	*Adhansia™XR* *Aptensio ™ XR* *Azstarys ™* *Cotempla XR-ODT™* *Focalin® IR & Focalin® XR* *Jornay PM* *Metadate CD® & Metadate ER®* *Methylin ER®, soln IR* *methylphenidate chew* *methylphenidate ER, LA, SR* *methylphenidate ER(generic Relexxii®)* *methylphenidate ER(generic Aptensio™ XR)* *methylphenidate (generic Daytrana®)* *Ritalin® IR, LA® & SR®* *Relexxii®* *QuilliChew ER™* *Quillivant™ XR susp*	

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Miscellaneous Drugs		
atomoxetine (generic for Strattera®) **clonidine ER** **guanfacine ER**	*Intuniv®* *Onyda™ XR* *Qelbree®* *Strattera®*	
♦ Narcolepsy Drugs		
armodafinil **modafinil** **Sunosi™**	*Nuvigil ™* *Provigil®* *Wakix®*	**Routine PDL edits plus** **♦All Narcolepsy Drugs require submission of Clinical SA. Refer to: Narcolepsy Medications SA Form**
Dermatologic		
***Acne Agents, Topical** *(AGE)*		
Combo Benzoyl Peroxide, Clindamycin, Erythromycin & other Top		**LENGTH OF AUTHORIZATIONS:** 1 year **Routine PDL edits plus** ***♦ Clinical Criteria for Dermatologic Acne Agents** • Prescriptions for members over the age of 18 years will require the submission of a SA to evaluate treatment diagnosis; **AND** • Drugs are intended for acne **only. SA for a cosmetic indication cannot be approved.**
Acne Medication gel, lot **benzoyl peroxide wash, cr, gel, lot (OTC)** **clindacin ETZ 1% pledget** **clindamycin ph 1% solution, pledget, swab, gel** **clindamycin/benzoyl peroxide (Duac®)** **erythromycin solution** **Panoxyl 4 Acne Cr Wash (OTC)** **Panoxyl 10 cleansing bar, foaming wash (OTC)**	*Acanya™ w/pump* *Acne Clearing System® (OTC)* *Aczone® Gel and Gel Pump* *Aklief®* *Amzeeq™* *Arazlo™* *Avar Cleanser, Medicated Pad* *Avar-E* *Avar-E LS* *Avar LS Cleanser, Medicated Pad* *Benzaclin®& Benzaclin® Pump* *BP 10-1* *Benzefoam™ regular &Ultra™* *Benzepro* *benzoyl peroxide wash/cr/gel/ lotion/foam/towelette (RX)*	

	Preferred Agents	Non-Preferred Agents	SA Criteria
		benzoyl peroxide 6%, 9% cleanser (OTC) *BPO Kit* *Cabtreo* *Cleocin T®* *Clindacin™ Pac Kit* *Clindagel®* *clindamycin phosphate (generic for Clindagel®)* *clindamycin/benzoyl peroxide (generic for Acanya® Pump, Benzaclin®, Onexton)* *clindamycin phosphate foam, el, lotion, med swab* *clindamycin/tretinoin (generic Veltin®)* *dapsone 5% gel* *Delos™ Lotion* *Duac® gel* *erythromycin gel/med. swab* *Evoclin™* *Inova™* *Lavoclen™Cleanser & Kit* *Neuac™ topical/kit* *Onexton™ gel & w/Pump* *Ovace® Wash* *Ovace® Plus shampoo/cr/lotion/foam* *Pacnex®HP & LP* *Panoxyl® 3% cr (OTC)* *Promiseb®Complete* *Rosula Cleanser* *Se BPO® Wash Kit & cleanser* *Sulfacetamide Cleanser ER* *Sulfacetamide Cleanser, Shampoo, Susp*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	Sulfacetamide Sodium/Sulfur Cr, Susp, Sunscreen *SSS 10-5 Foam* *Sulfacetamide/Sulfur/Cleanser, Cleanser Kit, Lotion Med. Pad* *Sulfacetamide/Sulfur/Urea Cleanser* *Sumadan Wash, Kit* *Sumadan XLT* *Sumaxin CP Kit* *Veltin®* *Winlevi®* *ZMA Clear Cleanser*	
Retinoids/Combinations, Topical		
adapalene gel OTC **Retin®A 0.025., 0.05, 0.1 % cr & 0.01, 0.025% gel**	*Acnefree® Severe Kit (OTC)* *adapalene 0.1% cr/gel/lot* *adapalene 0.3% gel/gel w/pump* *adapalene-benzoyl peroxide (gen Epiduo® and Epiduo® Forte)* *Altreno™* *Atralin® 0.05% gel* *Avage® 0.1% cr* *Avita® 0.025% cr/gel* *Differin® 0.1% cr/gel/lot RX* *Differin® 0.3% gel pump* *Differin 0.1% gel (OTC)* *Epiduo® & Epiduo® Forte Gel* **Fabior™0.1% Foam* *Renova® 0.02% cr/cr pump* *Retin®-A Micro 0.04%, 0.1% gel* *Retin®-A Micro 0.08%, 0.04%, 0.1% pump* *Tazorac® cr/gel* *tazarotene 0.1% cr, foam* *tretinoin 0.025, 0.1% cr & 0.01, 0.025, 0.05% gel*	*♦ **Age Edit for Fabior™ Foam** • Members must be between the ages of 12 and 18 years of age

Preferred Agents	Non-Preferred Agents	SA Criteria
	tretinoin microsphere 0.04%, 0.08%, & 0.1% gel *Twyneo®* *Ziana® gel*	
Antifungal Topical		
antifungal 1% cr, powder **antifungal 2% cr** **ciclopirox soln** **ciclodan 8% soln** **clotrimazole cr (OTC & RX)** **clotrimazole soln (OTC & RX)** **clotrimazole-betamethasone cr** **ketoconazole shampoo** **ketoconazole cr** **miconazole cr/spray (OTC)** **nystatin cr/oint/ powder** **terbinafine cr (OTC)** **tolnaftate cr/powder(OTC)**	*Alevazol® OTC* *Azolen® Tincture OTC* *Bensal HP®* *Ciclodan® Kit* *ciclopirox cr/shampoo/gel* *ciclopirox kit* *ciclopirox suspension* *clotrimazole-betamethasone lot* **CNL 8™ Kit* *Desenex® Aero Powder (OTC)* *econazole* *Ertaczo®* *Exelderm® cr & soln* *Extina®* *Fungi-Nail® (OTC)* *Fungoid® Kit (OTC)* *Fungoid® (OTC)* **Jublia®* *ketoconazole foam* **Kerydin®* *Lamisil AT® cr/gel (OTC)* *Lamisil® Spray (OTC)* *Loprox® Kit/ Shampoo/susp* *Lotrimin AF® cr (OTC)* *Lotrimin Ultra® (OTC)* *Lotrisone® cr* *luliconazole (generic for Luzu)* ***Luzu®* *miconazole nitrate (OTC)* *miconazole Oint/ powder (OTC)*	**LENGTH OF AUTHORIZATIONS: 6 months** **Routine PDL edits plus** **Select non-preferred topical Antifungals (CNL-8™, Jublia®, Kerydin™, Luzu®, Penlac®) require the submission of a Clinical SA. Refer to Antifungal Topical SA Form**

	Preferred Agents	Non-Preferred Agents	SA Criteria
		Mentax® *Naftin® cr/gel* *Naftifine CR* *Nyata Kit®* *Nizoral A-D® Shampoo (OTC)* *nystatin-triamcinolone cr/oint* *oxiconazole cr (generic Oxistat®)* *Oxistat® cr* *Oxistat® Lotion* *Pediaderm AF®* *PediPak®* **Penlac®* *tavaborole (generic Kerydin®)* *Tinactin® Aero powder/ spray(OTC)* *tolnaftate aero powde/spray (OTC)* *tolnaftate soln (OTC)* *Vusion®*	
	Immunomodulators Atopic Dermatitis	**CLOSED CLASS**	
	****Adbry™** ****Dupixent ®** ***Elidel®** ****Eucrisa™** ***pimecrolimus (AG)** ***tacrolimus**	****Opzelura™* *pimecrolimus (generic Elidel)* *Protopic®* *Zoryve cream, 0.15%* *Zoryve foam 0.3%*	LENGTH OF AUTHORIZATIONS: 1 year Routine PDL edits plus ♦ Clinical Criteria for Atopic Dermatitis-all drugs • Member must have an FDA approved diagnosis: Atopic dermatitis AND • Age and severity for drug as follows below: ○ Adbry™: moderate to severe for ages ≥ 12 years ○ Elidel®: mild to moderate for ages > 2 years ○ Eucisa™: mild to moderate for ages > 3 months ○ Dupixent®: moderate to severe for ages > 6 months ○ Opzelura™: mild to moderate for ages equal to or > 12 years ○ Protopic® 0.03%: moderate to severe for ages > 2 years. ○ Protopic® 0.1%: moderate to severe for ages > 16 years. ○ Zoryve cream, 0.15%; mild to moderate for ages ≥ 6 years. AND the one that applies:

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
		*__Clinical Criteria for Elidel,® pimecrolimus (AG), or tacrolimus__ • Prior documented trial & failure of 8 weeks of one (1) topical corticosteroid of medium to high potency (e.g., mometasone, fluocinolone) **__Clinical Criteria for Eucrisa™, Dupixent® and Adbry®__(reviewed electronically, AutoPA look back of 180 days for no more than a 30 day) • Prior documented trial & failure of 30-day trial (or contraindication) of o One (1) topical corticosteroid of medium to high potency (e.g., mometasone, fluocinolone) OR o One (1) topical calcineurin inhibitors (tacrolimus or pimecrolimus) *** __Clinical Criteria for Opzelura™ (topical Janus kinase inhibitor)__ • Prior documented trial & failure of 8 weeks of each o One (1) topical corticosteroid of medium to high potency (e.g., mometasone, fluocinolone) AND o One (1) topical calcineurin inhibitors (tacrolimus or pimecrolimus) AND ~~o~~ A trial and failure of Dupixent ® ~~AND~~ ~~o A trial and failure of Eucrisa™~~ • **Other indications: Opzelura cream can not be approved for the indication of nonsegmental vitiligo in adult and pediatric members ≥ 12 years old** __Clinical Criteria for Zoryve foam 0.3%__ • Member is 9 years of age or older and has a diagnosis of seborrheic dermatitis __QUANTITY LIMITS for Atopic Dermatitis__ **Drug** / **Rolling qty limit** Adbry® — 4 syringes/14 days (initial dose) 4 syringes/28 days (maintenance) Dupixent — 2 syringes (or pens)/14 days (initial dose), 2 syringes (or pens)/28 days (maintenance) Elidel® (pimecrolimus) — 30gm per 30 days Eucrisa® (crisaborole) — 300gm per year

Preferred Agents	Non-Preferred Agents	SA Criteria

Opzelura (ruxolitinib)	240 gm (4 x 60gm) per 30 days
Protopic® (tacrolimus)	30gm per 30 days

Dupixent other Diagnosis: Fax Form

♦ **Diagnosis of moderate to severe asthma**
Member must have moderate to severe asthma diagnosed as ONE of the following types:
- o Asthma with eosinophilic phenotype with eosinophil count ≥ 150 cells/mcL; OR
- o Oral corticosteroid dependent asthma with at least 1 month of daily oral corticosteroid use within the last 3 months; AND
- o Member must be 6 years of age or older

♦ **Diagnosis of eosinophilic esophagitis (EoE);**
- o Member ≥1 years old; AND
- o Member weighs ≥ 15 kg; AND
- o Prescribed by or consultation with an allergist or gastroenterologist; AND
- o Member did not respond clinically to treatment with a topical glucocorticosteroid or proton pump inhibitor

♦ **Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP)**;
- o Member ≥ 12 years old
- o Member has inadequate response after 3 consistent months use of preferred PDL intranasal steroids or oral corticosteroids; AND
- o Member is concurrently treated with intranasal corticosteroids

♦ **Diagnosis of Prurigo Nodularis for the treatment of adult members with prurigo nodularis (PN)**
- o Age 18 or older
- o Diagnosis of PN

♦ **Diagnosis of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype:**
- o Age 18 or older
- o Prescribed by or in consultation with a pulmonologist
- o Member has a diagnosis of COPD that is inadequately controlled and a minimum blood eosinophil count of 300 cells/mcL at screening, measured within the past 12 months

Preferred Agents	Non-Preferred Agents	SA Criteria
		o Member is receiving maximal inhaled therapy consisting of a long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA), and inhaled corticosteroid (ICS) (or therapy of LAMA plus LABA if ICS is contraindicated) o Member has a history of at least 2 moderate (requiring treatment with systemic corticosteroids and/or antibiotics) or 1 severe exacerbation(s) (resulting in hospitalization or observation for over 24 hours in an emergency department or urgent care facility) in the previous year, with 1 exacerbation occurring while the patient was on maximal inhaled therapy
Psoriasis, Topical		
calcipotriene cr/oint/soln	*betamethasone/ calcipotriene* *Calcitrene®* *calcitriol* *calcipotriene/betamethasone (generic for Taclonex®)* *Dovonex®* *Duobrii ™* **Enstilar ® Foam (AGE)* *Micanol®* *Sorilux™* *Taclonex® & Taclonex® Scalp* *Vectical™* *Vtama®* *Zoryve® 0.3% cream*	**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL edits plus** ***♦ Clinical Criteria for Enstilar ® Foam** • Length of Authorization: 4 weeks • Diagnosis of plaque psoriasis**; AND** • Minimum age of 18 years
Rosacea Agents, Topical		

Preferred Agents	Non-Preferred Agents	SA Criteria
metronidazole cr/gel	*azelaic acid (generic for Finacea®)* *brimonidine gel pump (generic Mirvaso®)* *Epsolay®* *Finacea® foam/gel* *ivermectin (generic Soolantra)* *Metrocream®* *Metrogel®* *metronidazole lot* *Mirvaso®* *Noritate®* *Rhofade®* *Rosadan™ Kit* *Soolantra®* *Zilxi™*	**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL edits**
Steroids		
Steroids, Topical Low Potency		**LENGTH OF AUTHORIZATIONS:** **1 year**
hydrocortisone cr/gel/lot/oint **hydrocortisone cr/oint OTC** **hydrocortisone/aloe cr OTC**	*anusol-hc 2.5% cr* *alclometasone cr/oint* *aqua glycolic HC* *Capex® shampoo* *Derma-smoothe-FS* *desonate gel/cr/lot/oint* *Desowen® lot* *fluocinolone 0.01% oil* *Micort™-HC* *Pediaderm® HC & Pediaderm® TA* *Scalpicin OTC* *Texacort®*	**Routine PDL edits**
Steroids, Topical Medium Potency		
fluticasone propionate cr/oint **mometasone furoate cr/oint/soln**	*betamethasone valerate foam* *Beser Lotion and Kit* *clocortolone cr*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	Cloderm® *Cordran® tape* *Cutivate® cr/lot* *Dermatop® cr/oint* *Elocon® cr/oint/soln* *fluocinolone acetonide cr/oint/soln* *flurandrenolide cr/oint/tape* *fluticasone propionate lot* *hydrocortisone valerate cr/oint* *hydrocortisone butyrate (generic for Locoid Lotion)* *hydrocortisone butyrate cr/oint/soln/ emollient* *Locoid Lipocream* *Locoid Lotion* *Luxiq®* *Momexin®* ~~*Pandel®*~~ *prednicarbate cr/oint* *Synalar®* *Synalar TS®* *Ticanase kit®*	
Steroids, Topical High Potency		**LENGTH OF AUTHORIZATIONS:** **1 year**
betamethasone valerate cr/lot/oint **triamcinolone acetonide cr/lot/oint**	*amcinonide cr/lot/oint* *betamet diprop & prop gly cr/lot/oint* *betamet diprop cr/foam/gel/lot/oint* *DermacinRx® SilaPak™* *DermacinRx® Silazone* *DermacinRx® Therazole Pak* *desoximetasone cr/gel/oint/spray* *desoximetasone (generic Topicort® spray)*	**Routine PDL edits plus** *♦ **Clinical Criteria for Sernivo™*** • Length of Authorization: 4 weeks (treatment beyond 4 weeks is not recommended). • Member must have diagnosis of mild to moderate plaque psoriasis: **AND** • At least 18 years of age

Preferred Agents	Non-Preferred Agents	SA Criteria
	diflorasone diacetate cr/oint *Diprolene® lot/oint* *DiproleneAF®cr* *Ellzia™ Pak Kit* *fluocinonide cr/ emollient/ gel/oint/soln* *halcinonide cr* *Halog® cr/oint/soln* *Kenalog® aerosol* *Loprox® Suspension Kit* **Sernivo™* *Silazone® II Kit* *Topicort® cr/gel/oint/spray* *Trianex® oint* *triamcinolone spray* *triamcinolone/dimethicone* *Vanos®cr* *Whytederm®Tdpak*	
Steroids, Topical Very High Potency		
clobetasol emollient **clobetasol propionate cr/gel/oint/soln** **halobetasol propionate cr**	*Apexicon™E* *Bryhali™ (halobetasol propionate)* *clobetasol lot/shampoo* *clobetasol propionate foam/spray* *Clobex® lot/shampoo/spray* *Clobetex® Kit* *Clodan® kit* *Halonate®* *halobetasol propionate oint (generic for Lexette®)* *Impeklo™* *Olux®* *Olux®-E* *Temovate® oint* *Ultravate® cr/lotion/oint*	

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
		Ultravate® PAC & Ultravate® X	
Endocrine and Metabolic Agents			
	Androgenic Agents (Testosterone – Topical)		
	AndroGel® Pump **Androderm® Patch** **testosterone pump (generic for AndroGel® Pump)**	*AndroGel® packet, patch* *Axiron® soln* *Fortesta®* *Natesto Nasal Gel ®* *Testim®* *testosterone (generic for Axiron®)* *testosterone gel/packet/pump (generic for Vogelxo™)* *testosterone (generic for Fortesta®)* *Vogelxo™ gel/packet/pump* *Xyosted™*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
	Antihyperuricemics		
	allopurinol 100mg and 300mg **colchicine tabs** **Probenecid®** **probenecid & colchicine**	*allopurinol 200MG* *colchicine caps* *Colcrys®* *febuxostat (generic Uloric®)* *Gloperba ®* *Mitigare®* *Uloric®*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
	Contraceptives*(long-acting IUDs & injectable)		
	Depo-Provera® 104mg **Kyleena™** **Liletta®** **medroxyprogesterone 150mg** **Mirena®** **Nexplanon®** **Paragard®**	*Depo-Provera® 150mg*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Skyla®		
Diabetes Hypoglycemics: Injectable Amylin Analogs		
	**SymLin®* **SymLin® Pens*	**LENGTH OF AUTHORIZATIONS**: 1 year ***Clinical Criteria for Injectable Amylin Analogs** • Member must have a history of at least a 90day trial of insulin. • SymLin® is only indicated as adjunct therapy with insulin. • Member meeting ALL of the following criteria may be approved: ○ Diagnosis of Type 1 or 2 diabetes; **AND** ○ On insulin therapy, **AND** ○ Failure to achieve adequate glycemic control (HbA1c ≤ 6.5%)
♦Diabetes Hypoglycemics: Injectable and Oral Incretin Mimetics CLOSED CLASS		
Byetta® **Trulicity™** **Victoza®**	*Bydureon™ Bcise SQ* *liraglutide* *Mounjaro®* *Ozempic®* *Rybelsus Tab®* *Soliqua® 100/33* *Tanzeum™* *Xultophy® 100/3.6*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits** **Preferred Agents Clinical Criteria:** • **Diagnosis of type II diabetes** **Non-Preferred Incretin Mimetics SA Form**
Diabetes Hypoglycemics: Injectable Insulins		
Insulin Mix		**LENGTH OF AUTHORIZATIONS: 1 year** **Routine PDL edits**
Humalog® Mix 50/50 vial **Humalog® Mix 75/25 vial** **Humulin® 70/30 pen/vial(OTC)** **insulin aspart/insulin aspart protamine vial**	*Humalog® Mix 50/50 Kwikpen* *Humalog® Mix 75/25 Kwikpen* *insulin lispro protamine mix kwikpen* *Novolin® 70/30 vial (OTC)* *Novolog® Mix 70/30 pen/vial*	

Preferred Agents	Non-Preferred Agents	SA Criteria
Insulin N		
Humulin® N pen/vial (OTC)	*Humulin® N pen* *Novolin® N vial (OTC)*	
Insulin R		
Humulin® R pen/vial	*Novolin® R vial (OTC)*	
Long-Acting Insulins		
Lantus® Solostar® & vial ***Toujeo Solostar ® pen**	*Basaglar® KwikPen®* *insulin degludec* *insulin glargine max solo u300* *insulin glargine solostar u300* *insulin glargine-yfgn* *insulin glargine pen and vial* *Rezvoglar® Kwikpen* *Semglee™* *Toujeo® Max Solostar®300 Units/mL* *Tresiba® FlexTouch® Pen 100 U/ml, 200 U/ml*	***Clinical Criteria for Toujeo Solostar:** • The member has tried and failed or is intolerant to Lantus
Rapid-Acting Insulins		
Humulin 500 U/M pen/vial **Humalog® vial/pen** **Humalog® Cartridge** **Humalog Kwikpen 100 unit/ml** **Humalog Jr. Kwikpen** **insulin lispro vial** **insulin lispro Jr. Kwikpen** **insulin lispro Pen** **insulin aspart cartridge pen/vial** **insulin aspart/insulin aspart protamine insulin pen**	*Admelog® Solostar Pen/vial* *Afrezza® cartridge (inhalation)* *Apidra® cartridge/Solostar/vial* *Fiasp®/FlexTouch®Pen/PenFill®* *Humalog Kwikpen 200 unit/ml* *Lyumjev™* *Novolog® cart/vial/Flexpen*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Diabetes Oral Hypoglycemics		
Oral Hypoglycemics Alpha-Glucosidase Inhibitors		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits plus** ♦Age edit for all Oral Hypoglycemics is 18 years of age or older, except Metformin which is 10 years of age.
acarbose	*Glyset®* *miglitol (generic Glyset®)*	
Oral Hypoglycemics Biguanides		
metformin **metformin ER** *(generic for Glucophage® XR)*	*Fortamet®* *Glucophage® IR & XR* *Glutmetza®* *Riomet® susp* *metformin 625 mg* *metformin ER (generic Fortamet®)* *metformin ER (generic Glumetza®)* *metformin (generic Riomet®)*	
Oral Hypoglycemics Biguanide Combination Drugs		
glyburide/metformin	*glipizide/metformin* *Glucovance®*	
Oral Hypoglycemics DPP-IV Inhibitors & Combination CLOSED		
Janumet® **Janumet XR®** **Januvia®** **Jentadueto™** **Jentadueto XR™** **Kombiglyze XR™** **Onglyza™** **Tradjenta™**	*alogliptin (generic Nesina™)* *alogliptin/metformin (generic Kazano™)* *alogliptin/pioglitazone (generic Oseni™)* *Glyxambi®* *Kazano™* *Nesina™* *Oseni™* *Qtern®* *saxagliptin hcl(generic Onglyza™)*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	saxagliptin/metformin ER (generic Kombiglyze XR™) *Steglujan™* *Trijardy™ XR* *Zituvio™* *Zituvimet™* *Zituvimet™ XR*	
Oral Hypoglycemics Meglitinides		
nateglinide **repaglinide**	*Prandin® & PrandiMet™* *repaglinide/metformin* *Starlix*	
Oral Hypoglycemics Second Generation Sulfonylureas		
glimepiride **glipizide** **glipizide ER** **glyburide** **glyburide micronized**	*Amaryl®* *Diabeta®* *Glucotrol®* *Glucotrol XL®*	
Oral Hypoglycemics Sodium Glucose Co-Transporter 2 Inhibitor CLOSED CLASS		
Farxiga™ **Jardiance®** **Synjardy®** **Synjardy® XR** **Xigduo™ XR**	*dapagliflozin* *dapagliflozin-metformin ER* *Inpefa™* *Invokana™* *Invokamet™* *Invokamet™ XR* *Segluromet™* *Steglatro™*	

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Oral Hypoglycemics Thiazolidinediones		
pioglitazone	*Avandia®* *Actoplus Met® IR & XR* *Actos®* *Avandaryl®* *Avandamet®* *Duetact®* *pioglitazone/metformin* *pioglitazone/glimepiride*	
Erythropoiesis Stimulating Proteins		
Epogen® **Retacrit™ (PFIZER)**	*Aranesp® vial/syringe* *Jesduvroq®* *Mircera®* *Procrit®* *Reblozyl®* *Retacrit™ (VIFOR)* *Vafseo®*	**LENGTH OF AUTHORIZATIONS**: for duration of the prescription up to 6 months **Routine PDL edits**
Glucagon Agents CLOSED CLASS		
Baqsimi nasal **Proglycem suspension oral** **Zegalogue Autoinjector & syringe SQ**	*Diazoxide suspension oral* *Glucagon emergency kit (Lilly) inj* *Glucagon inj* *Glucagon emergency kit (Fresenius and Amphastar) inj* *Gvoke pen, syringe, vial SQ*	**LENGTH OF AUTHORIZATIONS**: **1 year** **Routine PDL edits**
Glucocorticoids, Oral		
budesonide EC **dexamethasone soln/tab** **hydrocortisone** **methylprednisolone dose pk** **methylprednisolone 4 mg tab** **prednisolone sod phosph soln** **prednisolone soln**	*Alkindi® Sprinkle* *Cortef®* *cortisone acetate* *dexamethasone elixir/intensol* *Dexpak®* *Entocort® EC* *Eohilia™*	**LENGTH OF AUTHORIZATIONS**: **1 year** **Routine PDL edits**

Preferred Agents	Non-Preferred Agents	SA Criteria
prednisone soln/tab/dose pk	*Flo-Pred®* *Hemady®* *Medrol ® dose pk/tab* *methylprednisolone 8,16 & 32mg tab* *Millipred DP® tab Does Pk* *Millipred® soln/tab* *Orapred ®ODT* *Ortikos™* *prednisolone sod phosphate ODT/ soln* *prednisone intensol* *Rayos® DR tab* *TaperDex®* *Tarpeyo™* *Veripred®*	
***Growth Hormone** **CLOSED CLASS**		
Genotropin® Cartridge, Miniquick **Norditropin FlexPro®**	*Humatrope® cartridge/vial* *Ngenla™* *Nutropin AQ® NuSpin™* *Omnitrope® cartridge/vial* *Serostim® vial* *Skytrofa™* *Sogroya®* *Zomacton® vial*	**LENGTH OF AUTHORIZATIONS**: 1 year **♦ALL Growth Hormone drugs (preferred and non-preferred) require the submission of a Clinical SA. Refer to (Growth Hormone SA Fax Form)**
***Hereditary Angioedema (HAE) Agents**		
Berinert® **Cinryze™** **icatibant (generic Firazyr®)** **Kalbitor®** **Sajazir™**	*Firazyr®* *Haegarda®* *Orladeyo™* *Ruconest®* *Takhzyro™*	**LENGTH OF AUTHORIZATIONS:** 1 year **Routine PDL edits plus** ***♦ALL Hereditary Angioedema drugs (preferred and non-preferred) require the submission of a Clinical SA. Refer to Hereditary Angioedema (HAE) SA Form** ****Black box warning KALBITOR®** **Anaphylaxis has been reported after administration of KALBITOR®.** **Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and**

	Preferred Agents	Non-Preferred Agents	SA Criteria
			hereditary angioedema. Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and members should be monitored closely.
	***Pancreatic Enzymes**		
	Creon® **Zenpep®**	*Pancreaze®* *Pertzye®* *Ultresa®* *Viokace®*	**LENGTH OF AUTHORIZATION:** 1 year **Routine PDL edits plus** ***Clinical Criteria for Pancreatic Enzymes** • All drugs preferred and non preferred require a diagnosis of pancreatic insufficiency due to cystic fibrosis or chronic pancreatitis or pancreatectomy. • If a member has a diagnosis of Cystic Fibrosis they do not have to try and fail of a preferred. • If member has a feeding tube, then two different pancreatic enzymes can be approved for use together.
	Progestational Agents CLOSED CLASS		
	medroxyprogesterone acetate (tab only) **norethindrone acetate** **progesterone cap/inj**	*Aygestin®* *Crinone (Vaginal)* *Depo-Provera 400 MG/ML* *Prometrium®* *Provera®*	**LENGTH OF AUTHORIZATIONS:** 1 year **Routine PDL edits**
	Vaginal Estrogens		
	Premarin® Vaginal cr **Vagifem® Vaginal tab**	*Estrace ®Vaginal cr* *estradiol cream (gen Estrace®)* *estradiol vaginal tab* *Estring® Vaginal ring* *Femring® Vaginal ring* *Imvexxy®* *Intrarosa™* *Yuvafem®*	**LENGTH OF AUTHORIZATIONS:** 6 months **Routine PDL edits**
	Weight Management Agents CLOSED CLASS		
	orlistat **Xenical**	*Imcivree SQ* *Saxenda®*	**Length of authorization:** As indicated on fax form

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	phendimetrazine IR and ER **phentermine** **benzphetamine** **diethylpropion IR and ER**	*Wegovy®* *Zepbound™*	**Routine PDL edits plus** **Weight Management Agents SA Form** **GLP-1 Receptor Agonist For Cardiovascular Risk Reduction SA Form** ♦ The selected GLP-1 Receptor Agonist is Saxenda
Gastrointestinal			
	G I Antibiotics		
	Firvanq™ soln **metronidazole 250mg, 500mg tab** **vancomycin cap**	**Aemcolo™* *Alinia®* *Dificid®* *Flagyl® cap/ER* *Likmez™* *metronidazole 125mg tab* *metronidazole cap* *neomycin* *nitazoxanide (generic Alinia®)* *paromomycin* *Solosec®* *Tindamax®* *tinidazole* ***Xifaxan®* *vancomycin compounded oral soln kit* *vancomycin sol* *Vancocin®* ****Vowst™*	**Length of authorization:** 1 year **Routine PDL edits** ***♦Clinical Criteria for Aemcolo** • Diagnosis of travelers' diarrhea with moderate diarrhea that is distressing or interferes with planned activities AND • Documentation of a history of failure, contraindication, or intolerance to one or more of the following: Azithromycin (generic Zithromax), Ciprofloxacin (generic Cipro), Levofloxacin (generic Levaquin), Ofloxacin (generic Floxin) ****♦Clinical Criteria for Xifaxan** Xifaxan®: 200 mg tabs: − • Treatment of travelers' diarrhea caused by noninvasive strains of E. coli in members • ≥ 12 years of age – • Quantity limit = 9 tabs per claim • Length of authorization 1 month Xifaxan®: 550 mg tabs: − • Reduction in risk of overt hepatic encephalopathy recurrence in members ○ ≥ 18 years of age. ○ 2 tablets/day OR – • Treatment of irritable bowel syndrome with diarrhea (IBS-D) in members ○ ≥ 18 years of age – ○ 3 times a day for 14 days.

Preferred Agents	Non-Preferred Agents	SA Criteria
		○ 42 tablets /14 days, can be retreated up to two times with the same regimen. ○ Max 126 tablets per 365 days Length of authorization = 3 months ***♦ **Clinical Criteria for Vowst™:** • Member ≥ 18 years of age; AND • Member has a confirmed diagnosis of recurrent Clostridioides difficile infection (CDI) with a total of ≥3 episodes of CDI within 12 months; AND • Antibiotic treatment for recurrent CDI must be completed 2 to 4 days prior to initiation of Vowst therapy; AND • Member will take 10 oz of magnesium citrate (or 250 mL polyethylene glycol electrolyte solution for members with impaired kidney function) the evening prior to initiation of Vowst therapy; AND • Member must not have absolute neutrophil count (ANC) < 500 cells/mm3 , toxic megacolon, or small bowel ileus • Quantity limit = 12 capsules per 3 days • Renewal Criteria: Not applicable Length of authorizations: 30 Days
Antiemetic/Antivertigo Agents		
Cannabinoids (delta-9THC derivatives)		**LENGTH OF AUTHORIZATIONS:** 6 months
***dronabinol cap**	**Marinol ®* **Syndros®*	***Dronabinol plus all non-preferred Antiemetic/Antivertigo agents require submission of a Clinical SA. Refer to Antiemetic/Antivertigo SA form**
5HT3 Receptor Blockers		**LENGTH OF AUTHORIZATIONS:** 3 months, unless otherwise noted
ondansetron ODT/soln/tab	*Anzemet®* *Akynzeo®* *granisetron tab, vial* *ondansetron vial, amp, syringe* *palonosetron vial, syringe* *Sancuso® patch* *Sustol®*	**Routine PDL edits plus:** **For ondansetron 16mg ODT:** The member has tried and failed or is intolerant to ondansetron 8mg ODT.
NK-1 Receptor Antagonist		**LENGTH OF AUTHORIZATIONS:** Length of chemotherapy regimen or a

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	Aponvie™ *aprepitant capsule/pack* *Cinvanti™ (Intraven)* *Emend® Bi Pak/ cap* *Emend® Tri-fold pack/susp* *Emend® vial* *Focinvez™* *fosaprepitant vial*	maximum of 6 months
Other		**LENGTH OF AUTHORIZATIONS**: 1 year, unless otherwise noted
***Diclegis®** **meclizine (OTC, Rx)** **metoclopramide soln, tab, vial** ****Phenadoz® supp** **prochlorperazine tab** ****promethazine soln, syrp, tab** *(AGE)*	*Antivert®* *Barhemsys®* **Bonjesta™* *Compazine® supp/tab* *Compro®* *dimenhydrinate tab, vial* *doxylamine succinate/ vit B6* *Metozolv® ODT* *metoclopramide ODT* *****Phenergan® (AGE)* *prochlorperazine supp, vial* *****promethazine 50mg supp, vial, ampul (AGE)* *Reglan®* *scopolamine (gen Transderm-Scop®)* *Tigan®* *Transderm-Scop®* *trimethobenzamide*	****♦Promethazine products approved for members ≥ 2 years** ***♦Bonjesta®/Diclegis®:** Approve through EDD. member must be pregnant and at least 18 years of age.
***GI Motility, Chronic**		
****Linzess™** **lubiprostone and AG** **Movantik®**	*alosetron* *Amitiza®* *Lotronex®* *Motegrity™* *Relistor®*	**LENGTH OF AUTHORIZATIONS**: 6 months **Routine PDL edits plus**

Preferred Agents	Non-Preferred Agents	SA Criteria
	Symproic® *Trulance™* *Viberzi™*	***♦All GI Motility drugs (preferred and non-preferred) require the submission of a Clinical SA. Refer to Chronic GI Motility SA form** ****Pediatric use of Linzess 72 mcg only:** 1. Diagnosis of functional constipation (FC) 2. Member is 6 to 17 years of age 3. Prescriber attestation that other causes of constipation have been ruled out 4. Member has had treatment failure on at least TWO of the following: Osmotic Laxatives (i.e., lactulose, polyethylene glycol, sorbitol), OR Bulk Forming Laxatives (i.e., psyllium, fiber), OR Stimulant Laxatives (i.e., bisacodyl, senna)
H. Pylori Treatment		
Pylera®	*bismuth-metronidazole-tetracycline (gen Pylera®)* *Helidac®* *Omeclamox®-Pak* *lansoprazole/amoxicillin/clarithromycin* *Prevpac®* *Talicia®* *Voquezna®*	**LENGTH OF AUTHORIZATIONS**: 14 days **Routine PDL edits**
Laxatives & Cathartics CLOSED CLASS		
Bowel Prep Agents		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
Gavilyte-C solution **Gavilyte-G solution** **PEG 3350/electrolytes solution for reconstitution** **PEG-3350/flavor packs solution for reconstitution** **PEG 3350/electrolytes powder pack (AG) (authorized generic of Moviprep)**	*Clenpiq* *Golytely* *Moviprep Powder Pack and generics* *Nulytely With Flavor Packs* *Plenvu* *sodium, potassium,mag sulfates(generic Suprep)* *Suflave Powder* *Suprep* *Sutab*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Constipation		
lactulose solution	**Kristalose Packet*	*** Kristalose:** • Must have tried, failed or be intolerant to generic lactulose
Proton Pump Inhibitors		
omeprazole RX **pantoprazole** **Protonix® susp**	*Aciphex® DR tab/sprinkle* *dexlansoprazole dr (gen Dexilant®)* *Dexilant®* *esomeprazole magnesium cap/susp* *esomeprazole strontium* *lansoprazole cap* *Nexium®* *omeprazole OTC* *omeprazole magnesium OTC* *omeprazole/sodium bicarbonate* *pantoprazole susp (generic Protonix® susp)* *Prevacid® RX, OTC& SoluTab* *Prilosec® Rx & Susp* *Protonix®* *rabeprazole DR tab* *Zegerid® cap/OTC/susp packet*	**LENGTH OF AUTHORIZATIONS**: 12 weeks; unless member meets an exception; then 1 year **Routine PDL edits plus** ***♦All non-preferred Proton Pump Inhibitors require submission of a Clinical SA. Refer to Proton Pump Inhibitor SA form** **Preferred agents require a SA for use over 90 days**
Ulcerative Colitis Oral and Rectal Preparations (5-ASA DERIVATIVES)		
Ulcerative Colitis – Oral		**LENGTH OF AUTHORIZATIONS: 1 year** **Routine PDL edits**
Apriso® **balsalazide disodium** **Pentasa®** **sulfasalazine DR & IR**	*Asacol ®HD* *Azulfidine® IR &DR* *budesonide ER (generic Uceris™)* *Colazal®* *Delzicol™* *Dipentum* *Lialda®* *mesalamine (generic Apriso®)* *mesalamine (generic Asacol® HD)*	

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
		mesalamine (generic Lialda®) *Uceris™*	
	Ulcerative Colitis – Rectal		
	mesalamine rectal supp **mesalamine enema**	*Canasa® rectal supp* *mesalamine kit* *Rowasa® enema/kit* *SFRowasa®* *Uceris® foam*	
Genitourinary			
	Alpha-Blockers and Androgen Hormone Inhibitors For Benign Prostatic Hypertrophy (BPH)		
	Alpha-Blockers for BPH		**LENGTH OF AUTHORIZATIONS:** **1 year** **Routine PDL edits**
	alfuzosin **tamsulosin HCL**	*Flomax ®* *Rapaflo®* *silodosin (generic Rapaflo)* *Uroxatral®*	
	Androgen Hormone Inhibitors for BPH		
	dutasteride **finasteride 5 mg**	*Avodart ®* *dutasteride/tamsulosin* *Jalyn®* *Proscar®*	
	Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitor forBPH		
		Entadfi™	
	Phosphodiesterase (PDE) 5 Inhibitor for BPH		***Step edit for Cialis®** & tadalafil 2.5 and 5mg - trial and failure of Alpha Blockers and Androgen Inhibitors for BPH. Prescriber must attest that the member is not on the state's sex offenders list. Consult or evaulation by Urologist.
		**Cialis® (ST)* *tadalafil 5 mg (ST)*	
	Urinary Antispasmodics (Bladder Relaxant)		
	fesoterodine fumarate ER **Myrbetriq™ tab** **oxybutynin tab/syrup** **oxybutynin ER** **solifenacin**	*darifenacin ER (generic Enablex®)* *Detrol® & Detrol® LA* *Ditropan® & *Ditropan® XL* *flavoxate*	

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
		Gelnique™ gel/gel Pump *Gemtesa®* *Myrbetriq™ Granules* *Oxytrol® transdermal includes OTC* *Sanctura XR* *trospium IR & ER* *tolterodine IR & ER* *Toviaz™* *VESIcare® and LS*	
Immunological Agents			
	***♦Multiple Sclerosis**	**CLOSED CLASS**	
	Avonex® **Avonex® Adm Pack** **Betaseron®** **Copaxone 20 mg syringe®** **dimethyl fumarate and Starter Pack** **fingolimod** ****Kesimpta® (ST)** **teriflunomide (generic Aubagio®)**	*Aubagio®* *Bafiertam™* *Briumvi™* *Copaxone® 40 mg syringe®* *Extavia® Kit* *Gilenya®* *glatiramer 20 mg/ml syringe* *Glatopa™* *Mavenclad®* *Mayzent®* *Ocrevus®* *Plegridy®* *Ponvory™* *Rebif® SQ* *Rebif® Rebidose Pen®* *Tascenso ODT™* *Tecfidera®* *Tecfidera® Starter Pack* *Tysabri®* *Vumerity™* *Zeposia®*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits plus** ***Adherence to the documented PI age and diagnosis required, reviewed electronically, AutoPA** ****Kesimpta® requires step trial of dimethyl fumarate (generic Tecfidera®) or a preferred Injectable agent, to be determined by an AutoPA.** **Multiple Sclerosis SA Form** **Briumvi SA Form** **Ocrevus SA Form** **Tysabri SA Form**

Preferred Agents	Non-Preferred Agents	SA Criteria
Drugs to improve walking in members with (MS)		
dalfampridine ER (generic Ampyra®)	*Ampyra®*	**Amprya® and dalfampridine ER require the submission of a Clinical SA.** **Refer to MS - Ampyra® SA form**
♦Cytokine and CAM Antagonists And Related Agents		**CLOSED CLASS**
Enbrel® Pen, Sureclick, Syringe, Vial **Humira® Pen, Syringe** **infliximab (gen Remicade®)** **methotrexate tab/PF vial/MDV**	*Abrilada™* *Actemra® SQ & ACTPEN* *adalimumab-aacf* *adalimumab-aaty* *adalimumab-adaz* *adalimumab-fkjp Pen* *adalimumab-ryvk* *Amjevita™* *Amjevita™ Autoinjector* *Arcalyst®* *Avsola™* *Bimzelx®* *Cibinqo™* *Cimzia® & Cimzia® Syringe Kit* *Cosentyx™* *Cosentyx™ UnoReady pen* *Cyltezo®* *Enspryng™* *Entyvio®* *Hadlima™* *Hulio®* *Hyrimoz®* *Idacio®* *Ilaris®* *Ilumya™* *Inflectra®* *Kevzara® inj, pen* *Kineret®* *Olumiant®* *Omvoh™* *Orencia®* *Otezla®*	**LENGTH OF AUTHORIZATION**: 1 year **Routine PDL edits plus** ***All non-preferred Cytokine and CAM Antagonists require submission of a Clinical SA.** **Refer to Cytokine and CAM Antagonists and Related Agents SA Form** **** See Cytokine and CAM Antagonists Appendix A for Clinical Criteria**** For a list of Cytokine and CAM Antagonists and criteria for approval see **Appendix A**

	Preferred Agents	Non-Preferred Agents	SA Criteria
		Otrexup® *Rasuvo™* *RediTrex®* *Remicade®* *Renflexis®* *Rinvoq®* *Rinvoq® LQ* *Skyrizi™ syringe, Pen* *Siliq®* *Simlandi™* *Simponi®* *Simponi®Aria* *Spevigo®* *Stelara® vial/syringe* *Sotyktu™* *Taltz®* *Tofidence™* *Tremfya™* *Trexall®* *Tyenne®* *Uplizna®* *Velsipity®* *Xatmep™* *Xeljanz™, Xeljanz™ XR and solution* *Yuflyma®* *Yusimry™* *Zymfentra™*	
Ophthalmic			
	Antibiotics		
	bacitracin/polymyxin b sulfate oint **ciprofloxacin drops** **erythromycin** **gentamicin drops/oint**	*AzaSite™ drops* *bacitracin* *Besivance® drops* *Ciloxan® drops/oint* *Garamycin ®drops/oint* *gatifloxacin 0.5% soln*	**LENGTH OF AUTHORIZATIONS**: Date of service only; no refills **Routine PDL edits**

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
moxifloxacin drops (generic Vigamox) **ofloxacin drops** **polymyxin/trimethoprim** **tobramycin**	*Ilotycin®* *levofloxacin drops* *moxifloxacin drops (generic Moxeza®)* *Natacyn®* *neomycin/polymix/gramicidin* *neomycin/bacitracin/polymyxin oint* *Neosporin ®* *Ocuflox®* *Polytrim®* *sulfacetamide oint/ soln* *Tobrex® drops/oint* *Vigamox®* *Zymaxid®*	
Antibiotic/Steroid Combinations		
neomycin/polymyxin/dexamethasone oint/susp **sulfacetamide/prednisolone** **Tobradex® oint/susp** **tobramycin/dexamethasone susp**	*Blephamide® S.O.P.* *Maxitrol® oint/susp* *neomycin/bacitracin/poly/HC* *neomycin/polymyxin/HC* *Pred-G®oint* *Tobradex® ST* *Zylet®*	**LENGTH OF AUTHORIZATION**: Date of service only; no refills **Routine PDL edits**
Antihistamines/Mast Cell Stabilizers		
Antihistamines		**LENGTH OF AUTHORIZATIONS:** 1 year **Routine PDL edits**
Alaway OTC® **ketotifen fumerate** **olopatadine (generic Patanol & Pataday)** **Zaditor® OTC**	*alcaftadine (gen Lastacaft®)* *bepotastine (gen Bepreve®)* *Bepreve®* *Elestat®* *epinastine 0.05% eye drops* *Lastacaft®* *Optivar®* *Patanol® Rx and OTC* *Pataday® Rx and OTC*	

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	Zerviate ™	
Mast Cell Stabilizers		
cromolyn sodium	*Alocril*® *Alomide*®	
Anti-inflammatory Agents		
Corticosteroids		
Durezol® **fluorometholone** **prednisolone acetate**	*Alrex*™ *Dexamethasone* *difluprednate (gen Durezol*®*)* *Flarex*® *FML*®*, FML Forte*® *loteprednol etabonate* *Lotemax*™ *drops/gel/oint* *Maxidex*® *Omnipred*® *Pred Forte*® *& Pred Mild*® *prednisolone sod phosphate* *Vexol*®	
Immunomodulators CLOSED CLASS		
Restasis® **Restasis Multidose**® **Xiidra**®	*Cequa*™ *cyclosporine* **Eysuvis* *Miebo*™ *Tyrvaya*™ *Nasal Spray* ***Verkazia*®	*♦DUR DURATION LIMIT Eysuvis 1 bottle in 3 months, message returned to pharmacist stating "Limitation Exceeded: Quantity Limit of 1 Bottle per 3 Months. Member needs Intraocular Pressure (IOP) Test. If IOP test completed, Physician to call 1-800-932-6648 for a Clinical SA" **♦**Verkazia criteria (PDL criteria do not apply)** • Member is ≥4 years of age; **AND** • Diagnosis of moderate to severe vernal keratoconjunctivitis; **AND** • Trial and failure, contraindication, or intolerance to one of the following:

Preferred Agents	Non-Preferred Agents	SA Criteria
		o Topical ophthalmic "dual-action" mast cell stabilizer and antihistamine (e.g., olopatadine, azelastine) **OR** o Topical ophthalmic mast cell stabilizers (e.g., cromolyn); **AND** • Prescribed by ophthalmologist or optometrist in consultation with an ophthalmologist • Quantity Limit: 120 single-dose vials per 30 days • Length of approval: 1 year
NSAIDs		**LENGTH OF AUTHORIZATIONS**: Date of service only; no refills **Routine PDL edits** *Ilevro™ is limited to 1 bottle plus 1 refill
diclofenac sodium **flurbiprofen sodium** **ketorolac 0.5%**	*Acular® 0.5% & LS® 0.4%* *Acuvail®* *bromfenac sodium 0.07%* *bromfenac sodium 0.075%* *bromfenac 0.09%* *BromSite ™* **Ilevro™0.3% (QL)* *Inveltys ™ (loteprednol etabonate)* *Ketorolac LS 0.4%* *Nevanac®* *Ocufen®* *Prolensa™*	
Glaucoma Agents		
Alpha 2 Adrenergic Agents		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
Alphagan P® 0.1 & 0.15% **brimonidine 0.2%**	*apraclonidine 0.5% drops* *brimonidine tartrate 0.1 &0.15%* *Iopidine® 0.5% & 1%*	
Beta Blockers		
carteolol 1%	*Betagan® 0.5%*	

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Combigan® **levobunolol 0.5%** **metipranolol 0.3%** **timolol maleate**	*betaxolol 0.5%* *~~Betoptic S® 0.25%~~* *brimonidine-timolol (gen Combigan®)* *Istalol® 0.5%* *timolol (generic for Timoptic Ocudose)* *Timoptic® drops 0.25% & 0.5%* *Timoptic® XE 0.25% & 0.5% soln-gel*	
Carbonic Anhydrase Inhibitors		
Azopt® **dorzolamide** **dorzolamide/timolol**	*brinzolamide* *Cosopt® 0.5%-2%* *Cosopt® PF* *Simbrinza™* *Trusopt® 2%* *dorzolamide/timolol PF*	
Cholinergic Muscarinic Receptor Agonist		*Indicated for the treatment of presbyopia in adults
	**Vuity™*	
Rho Kinase Inhibitor		
Rhopressa® **Rocklatan**		
Prostaglandin Analogs		
latanoprost **Travatan Z®**	*bimatoprost* *Iyuzeh™* *Lumigan® 0.03% & 0.01%* *Rescula®* *tafluprost* *travoprost 0.004%* *Vyzulta™* *Xalatan® 0.005%* *Xelpros® (latanoprost)* *Zioptan™*	

Virginia's Medicaid Preferred Drug List (PDL)/ Common Core Formulary

1/1/25

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
Respiratory		
***Anti-Allergens, Oral**		
Grass Pollen		**LENGTH OF AUTHORIZATIONS**: 1 year ***♦All non-preferred Anti-Allergen drugs require the submission of a Clinical SA. Refer to Anti-Allergens, Oral SA Form or Palforzia SA Form**
	**Grastek®* **Odactra®* **Oralair® SL* **Ragwitek™*	
Peanut		
	**Palforzia™*	
Antihistamines: First and Second Generation		
First Generation Antihistamines		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
Generic only class	*All Brands require a SA*	
Second Generation Antihistamines and Combinations		
cetirizine liquid 1mg/1mL (RX/OTC) **cetirizine tabs OTC** **levocetirizine tab/OTC** **loratadine tab/syrup OTC**	*cetirizine chew tab (OTC)* *cetirizine liquid 5mg/5mL (OTC)* *cetirizine D tab (OTC)* *Clarinex®* *Clarinex-D®* *desloratadine ODT* *fexofenadine* *fexofenadine/PSE ER* *fexofenadine suspension* *loratadine ODT* *loratadine D 12 & 24 hr*	
Beta-Adrenergic Agents		
Long Acting Beta Adrenergic s (LABA) MDIs or Nebulizers		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
arformoterol (authorized generic Brovana®) **Serevent Diskus®**	*arformoterol (generic Brovana®)* *Arcapta DS* *Brovana®*	

Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	formoterol fumarate (generic Perforomist®) *Perforomist®* *Striverdi® Respimat*	
Short Acting Metered Dose Inhalers or Devices		
ProAir® RespiClick **Ventolin® HFA**	*albuterol HFA (Proair®)* *albuterol HFA (Ventolin®)* *albuterol HFA (Proventil®)* *levalbuterol tartrate HFA* *Xopenex® HFA*	
Short Acting Nebulizers		
albuterol sulfate (premixed)	*levalbuterol soln* *Xopenex®*	
COPD: Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors CLOSED CLASS		
Short Acting Anticholinergics/Short ActingBronchodilators CLOSED CLASS		
Atrovent HFA® **ipratropium bromide soln**		
Short Acting Anticholinergics/Short ActingBronchodilators CLOSED CLASS		
Combivent® Respimat **ipratropium/albuterol nebs**	*Bevespi Aerosphere™* *Duaklir Pressair*	**LENGTH OF AUTHORIZATION**: 1 year **Routine PDL edits**
Long Acting Anticholinergics CLOSED CLASS		
Spiriva® **Spiriva® Respimat**	*Incruse™ Ellipta®* *Lonhala™ Magnair™* *tiotropium (generic for Spiriva®)* *Tudorza™* **Yupelri™ (revefenacin)*	**LENGTH OF AUTHORIZATION**: 1 year **Routine PDL edits plus** ***Clinical Criteria Yupelri™ (**reviewed electronically, AutoPA**)** • Diagnosis of COPD **AND** • Trial/failure of Spiriva® Handihaler OR Spiriva® Respimat

Preferred Agents	Non-Preferred Agents	SA Criteria
Long Acting Anticholinergics/Long ActingBronchodilators CLOSED CLASS		
Anoro™ Ellipta® (AGE) **Stiolto Respimat™ (AGE)**		**LENGTH OF AUTHORIZATION**: 1 year **Routine PDL edits**
Phosphodiesterase 3 (PDE3) inhibitor and Phosphodiesterase 4 (PDE4) inhibitor CLOSED CLASS		
	Ohtuvayre™	
Phosphodiesterase 4 (PDE4) Inhibitors CLOSED CLASS		
***roflumilast**	**Daliresp®*	**LENGTH OF AUTHORIZATION**: 1 year ***Clinical Criteria for Daliresp® and roflumilast** • If the member has a diagnosis of severe COPD associated with chronic bronchitis and a history of exacerbations; **AND** • Trial/failure on at least one first-line or second-line agent (inhaled anticholinergics, long-acting beta agonists or inhaled corticosteroids); **AND** • Adjunctive therapy (Daliresp® must be used in conjunction with first-line or second-line agent).
Corticosteroids: Inhaled and Nasal Steroids		
Inhaled Corticosteroids: Combination Drugs (Glucocorticoid and Long Acting Beta Adrenergic) CLOSED CLASS		**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**
Advair® Diskus **Advair® HFA** **Dulera®** **Symbicort®** **Trelegy® Ellipta**	~~*AirDuo® Digihaler®*~~ *Airduo™ Respiclick®* *budesonide-formoterol (generic Symbicort®)* *Breo®Ellipta™* *Breyna™ (generic Symbicort®)* *Breztri Aerosphere™* *fluticasone/salmeterol (generic Airduo)* *fluticasone/salmeterol powder (generic Advair)*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	fluticasone/salmeterol HFA (generic Advair HFA) *fluticasone-vilanterol (generic Breo®Ellipta™)* *Wixela® (fluticasone/salmeterol)*	
Inhaled Corticosteroids: Metered Dose Inhalers CLOSED CLASS		
Alvesco® **Arnuity™ Ellipta®** **Asmanex Twisthaler** **Asmanex HFA®** **Flovent® Diskus** **Flovent® HFA** **QVAR® Redihaler** **Pulmicort Flexhaler®**	*Aerospan™* *~~ArmonAir® Digihaler™~~* *fluticasone HFA(gen Flovent® HFA)* *fluticasone Diskus (gen Flovent® Diskus)*	
Inhaled Corticosteroids: Nebulizer Solution CLOSED CLASS		**LENGTH OF AUTHORIZATIONS**: 1 year
budesonide respules	*Pulmicort® Respules*	
Nasal Steroids		**Routine PDL edits**
Dymista® **fluticasone Rx**	*azelastine/fluticasone nasal spray (generic for Dymista®)* *budesonide (generic for Rhinocort® Aqua)* *budesonide (generic Rhinocort® Allergy OTC)* *Children's Qnasl™* *Clarispray OTC* *Flonase®* *Flonase Sensimist (OTC)* *flunisolide* *fluticasone OTC* *ipratropium bromide spray* *mometasone (generic Nasonex®)* *Nasonex OTC*	

Preferred Agents	Non-Preferred Agents	SA Criteria
	Omnaris® *Qnasl™* *Rhinocort Aqua®* *Rhinocort® Allergy OTC* *Ryaltris®* *Ticanase®* *triamcinolone OTC* *triamcinolone acetonide* *Veramyst®* *Xhance™* *Zetonna™*	
Epinephrine, Self-Injected		
epinephrine 0.15 mg & 0.3 mg (authorized generic EpiPen® & EpiPen® Jr) **Epipen®** **Epipen® Jr**	*Auvi-Q®* *epinephrine 0.15 mg & 0.3mg (generic EpiPen® and EpiPen® Jr)* *epinephrine 0.15mg & 0.3mg (generic Adrenaclick)* *Symjepi™ (epinephrine)*	**LENGTH OF AUTHORIZATIONS**: **1 year** **Routine PDL edits**
***♦ Immunomodulators, Asthma CLOSED CLASS**		
Fasenra Pen **Fasenra Syringe** **Xolair Autoinjector** **Xolair Syringe** **Xolair Vial**	*Cinqair* *Nucala Auto-Injector* *Nucala Syringe* *Nucala Vial* *Tezspire Pen* *Tezspire Syringe*	**LENGTH OF AUTHORIZATIONS**: **see fax forms** **Routine PDL edits plus** ***♦ All Agents require the submission of a Clinical SA. Refer to fax forms below:** **Cinqair SA Form** **Fasenra SA Form** **Nucala SA Form** **Tezspire SA Form** **Xolair SA Form**
Intranasal Antihistamines		
azelastine 0.1%	*Astepro® 0.15%*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**

	Preferred Agents	*Non-Preferred Agents*	*SA Criteria*
	Leukotriene Receptor Antagonists		
	montelukast tabs/chewable tabs	*Accolate®* *Singulair® tabs/chew* *tabs/granules* *montelukast granules* *zafirlukast* *Zyflo™* *Zyflo CR™* *zileuton ER*	**LENGTH OF AUTHORIZATIONS**: 1 year **Routine PDL edits**